Clinical trial NCT05083949
Conditions: Healthy
Sponsor: Boehringer Ingelheim
Start date: 2021-07-23; Completion date: 2021-09-09
Enrollment: 32 participants; Allocation: RANDOMIZED; Intervention model: CROSSOVER

Brief summary:
This trial is to establish bioequivalence of the fixed dose combination (FDC) tablets (containing 12.5 mg empagliflozin/850 mg metformin) (Test, T) compared with the single tablets (10 mg empagliflozin and Glifage® 850 mg tablets) (Reference, R).

Detailed description:

Arms: arm 1: On Day 1 of Period 1 subjects received treatment A: Single dose tablet of 10 milligram(mg) empagliflozin film-coated and a 850mg of metformin hydrochloride (HCl) (Glifage®) tablet, orally with 200 milliliter(mL) of water.

On Day 1 of Period 2 subjects received treatment B: Fixed dose combination (FDC) tablet of 12.5mg empagliflozin/850 mg metformin HCl, orally with 200mL of water.

A high-fat, high-calorie meal was served 30 minutes(min) before drug administration. The treatments were separated by a wash-out phase of at least 7 days. arm 2: On Day 1 of Period 1 subjects received treatment B: Fixed dose combination (FDC) tablet containing 12.5 milligram (mg) empagliflozin/850 mg metformin HCl, orally with 200 milliliter (mL) of water.

On Day 1 of Period 2 subjects received treatment A: Single dose tablet of 10mg empagliflozin and 850 mg of metformin hydrochloride (HCl) (Glifage®) tablet, orally with 200mL of water.

A high-fat, high-calorie meal was served 30 minutes (min) before drug administration. The treatments were separated by a wash-out phase of at least 7 days.
Interventions: intervention 1: FDC 12.5mg empagliflozin/850mg metformin intervention 2: Empagliflozin intervention 3: Glifage®
Intervention descriptions: intervention 1: empagliflozin/metformin intervention 2: empagliflozin 10mg (R1) intervention 3: Glifage® 850mg (R2)

Protocol documents:
Prot_SAP_000.pdf: 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
 
Clinical Trial Protocol 
TITLE PAGE 
Document Number: <c12345678-01> 
 Number: PBDS004/21 
BI Trial No. 
1276-0041 
 Number 
PBDS004/21 
BI Investigational 
Medicinal Product 
 
JardianceDuo®, empagliflozin/metformin Fixed Dose Combination 
(FDC) 
Title 
Relative bioavailability of empagliflozin/metformin fixed-dose combination  - 
Empaglifozin 12.5 mg + Metformin 850mg (Boehringer Ingelheim) coated tablet 
versus Jardiance® 10mg (Reference 1: Boehringer Ingelheim) coated tablet and 
Glifage® 850mg (Reference 2:
 ) coated tablet, administered 
together in healthy male and female subjects under fed conditions: an open-label, 
randomised, single-dose, two-way crossover study. 
 
Clinical Phase 
I 
Trial Clinical 
Monitor 
Phone: 
 
Fax: 
 
Principal 
Investigator 
 
Address: 
 
 
Phone: 
 
Fax: 
  
Status 
Official Final Protocol  
Version and Date 
Version: 2.0  
Date: 08 Jun 2021 
Page 1 of 76 
Proprietary confidential information 
© 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies. All rights reserved. 
This document may not - in full or in part - be passed on, reproduced, published or otherwise used without prior written permission 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 2 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
CLINICAL TRIAL PROTOCOL SYNOPSIS 
BI trial number 
1276-0041 
 number 
PBDS004/21 
Title of trial 
Relative bioavailability of empagliflozin/metformin fixed-dose combination  - 
Empaglifozin 12.5 mg + Metformin 850mg (Boehringer Ingelheim) coated tablet 
versus Jardiance® 10mg (Reference 1: Boehringer Ingelheim) coated tablet and 
Glifage® 850mg (Reference 2:
 ) coated tablet, administered together 
in healthy male and female subjects under fed conditions: an open-label, 
randomised, single-dose, two-way crossover study. 
 
Principal Investigator:  
Clinical Investigator 
Trial sites 
Clinical phase: 
  
 
Clinical phase 
I 
Trial rationale 
According to ANVISA, Brazilian Health Authority, a BE program must be 
conducted as part of the Empa +Met FDC registration. The BE trial must be 
performed as per specific local requirements following ANVISA regulation. 
Trial objective 
To establish whether a fixed-dose tablet of 12.5 mg empagliflozin+850 mg 
metformin (T1) is bioequivalent to the free dose combination of 10 mg Jardiance 
(empagliflozin) and Glifage 850 mg (metformin) (R). 
Trial design 
Randomised, single dose, open-label, two-way crossover design  
Trial endpoints: 
Primary endpoints:  
• 
Dose-normalized AUC0-tz and Dose-normalized Cmax of empagliflozin  
• 
AUC0-tz and Cmax of  metformin  
Secondary endpoint:  
• 
Dose-normalized AUC0-∞ of empagliflozin  
• 
AUC0-∞ of metformin  
• 
Tmax AUC_%Extrap_obs, HL_Lambda_z and Lambda_z of 
empagliflozin and metformin 
Number of subjects  
 
 
total entered 
 N = 32  
 
each treatment 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 3 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Main criteria 
for inclusion 
Healthy male/female subjects, age > 18 years (inclusive) < 50 years (inclusive), 
body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive). 
Test product 
Drug formulation (T) 
 
dose 
Fixed-dose tablet of 12.5 mg empagliflozin+850 mg metformin 
 
mode of admin. 
Oral fed state with 200 mL of water after an overnight fast of at least 10 h and 30 
min after start of a 1000 Cal high fat/high caloric meal. 
Reference products 
Drug formulation (R1 and R2) 
 
dose 
Glifage (metformin) 850 mg – Reference 2 
Jardiance (empagliflozin) 10 mg – Reference 1 
 
mode of admin. 
Oral fed state with 200 mL of water after an overnight fast of at least 8 h and 30 
min after start of a 1000 Cal high fat/high caloric meal. 
Duration of treatment 
One day (single dose) for each treatment  
PK Collection Time 
points 
In each period of the study blood will be collected at the following time points: at 
pre dose (-00:05 minutes) and 00:15, 00:30, 00:45 minutes, and 01:00, 01:15, 
01:30, 01:45, 02:00, 02:20, 02:40, 03:00, 03:30, 04:00, 04:30, 05:00, 05:30, 06:00, 
07:00, 08:00, 10:00, 12:00, 24:00, 48:00, and 72:00 hours after the medication 
dosing on Day 1 of Periods 1 and 2. 
Statistical methods 
The assessment of bioequivalence will be based upon 2-sided 90% confidence 
intervals (CIs) for the ratios of the geometric means (test/reference) for the primary 
endpoints and for secondary endpoints for Dose-normalized AUC0-∞ 
(empagliflozin) and AUC0-∞ (metformin) using an acceptance range of 80.00 to 
125.00%. This method corresponds to the two 1-sided t-tests procedure, each at a 
5% significance level. The statistical model will be an analysis of variance 
(ANOVA) on the logarithmic scale including effects for sequence, subjects nested 
within sequences, period and treatment. CIs will be calculated based on the residual 
error from the ANOVA and quantiles from the t-distribution. 
Differences in tmax, will be analysed using a non-parametric method. 
 
Descriptive statistics will be calculated for all endpoints. 
 
 
 
 
 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 4 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Responsible for the phases of study 
Study Sponsor 
Boehringer Ingelheim 
 
Principal Investigator 
 
Clinical Investigator 
 
Phase - Institution 
Responsible 
Qualification 
Clinical Phase -  
 
Pharmacist  
Laboratorial Exams execution 
 Pharmacist 
Biochemisty 
Analytical Phase – 
 
 
Food Chemist 
Statistical Phase - 
 
Statistical and 
Mathematics 
Quality Assurance -
 
Biomedical 
 
 
 
 
 
 
 
 
 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 5 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
 
Study researchers signature 
This project will be conducted according to the norms and rules of research with human beings 
as in Resolution Nº 466/12 and 251/97 of the National Health Committee – Health Ministry, 
of ICH`s GLP – Good Laboratory Practices according ICH and the Document of the Americas 
and the Helsinki Declaration (1964) also the Tokyo review (1975), Venice’s  review (1983), 
Hong Kong’s review (1989),  Somerset West’s review  (1996), Edinburg’s review (2000), 
Washington’s review (2002), Tokyo’s (2004) and Seoul’s review (2008) and Fortaleza (2013).  
 
Study Sponsor 
 
Boehringer Ingelheim._________________________________________Date___/___/___. 
 
’s team 
 
Principal Investigator 
 
_______________________________Date ___/___/___. 
Clinical Investigator 
 
_________________________________Date___/___/___. 
 
 
 
 
 
 
 
 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 6 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
STUDY PHASES EXECUTION PLACES 
Subjects’ Clinical Assessment Place: 
Clinical Research Unit: 
. 
Address: 
 
, Zip Code: 
 
Phone number: 
 
Clinical Phase Execution Place: 
Clinical Research Unit:
 
Address
 
 Zip Code: 
 
Phone number: 
 
Execution Place of the Laboratorial Clinical Exams: 
 
 
Address: 
 
 
Phone number: 
 
 
Analytical Phase Execution Place: 
  
 
Address: 
 
ZIP CODE: 
 
PHONE/FAX: 
 
E-mail: 
 
 
Statistical Phase Execution Place: 
Statistical Unit: 
 
Address:
 
 Zip Code: 
 
Phone number: 
 
Ethics Committee responsible for the evaluation and protocol approval:  
Comitê de Ética em Pesquisa do 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 7 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 8 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
FLOW CHART 
Period 
Visit 
Day 
Planned time (relative to 
first drug administration) 
[h:min]
Approximate clock time  
of actual day [h:min] 
Event and comment 
Safety laboratory 
PK blood 
12-lead ECG 
Additional examination 
Vital signs (BP, HR, temp) 
Questioning for AEs and concomitant 
therapy 6 
SCR 
1 
-28 to -1 
 
 
Screening (SCR)1 
x 
 
x 
 
x 
x 
 
 
-2 
 
 SARS-COV-2 RT-PCR via nasal swab 
 
 
 
x 
 
 
1/2 (two identical periods with separated by a wash-out of at least 7 days 
2/3 
-1 
-17:00 
17:00 Admission to trial site 
x5 
 
 
 
 
x 
-17:00 
17:00 Allocation to treatment2 (visit 2 only) 
 
 
 
 
 
 
-11:30 
20:30 Dinner (voluntary) 
 
 
 
 
 
 
1 
-07:00 
00:00 Water ingestion restriction 
 
 
 
 
 
 
-01:00 
06:00  
 
 
 
 
 
x 
-0:30 
06:30 High fat, high calorie breakfast  
 
 
 
 
 
 
-0:05 
06:55  
 
x 
 
 
x 
 
0:00 
07:00 Drug administration 
 
 
 
 
 
 
0:15 
07:15  
 
x 
 
 
 
 
0:30 
07:30  
 
x 
 
 
 
 
0:45 
07:45  
 
x 
 
 
 
 
1:00 
08:00  
 
x 
 
 
x 
x 
1:15 
08:15  
 
x 
 
 
 
 
1:30 
08:30  
 
x 
 
 
 
 
1:45 
08:45  
 
x 
 
 
 
 
2:00 
09:00 200 mL fluid intake 
 
x 
 
 
x 
 
2:20 
09:20  
 
x 
 
 
 
 
2:40 
09:40  
 
x 
 
 
 
 
3:00 
10:00  
 
x 
 
 
x 
 
3:30 
10:30  
 
x 
 
 
 
 
4:00 
11:00 Lunch 
 
x 
 
 
x 
 
4:30 
11:30  
 
x 
 
 
 
 
5:00 
12:00  
 
x 
 
 
 
 
5:30 
12:30  
 
x 
 
 
 
 
6:00 
13:00  
 
x 
 
 
x 
 
7:00 
14:00  
 
x 
 
 
 
 
8:00 
15:00 Snack (voluntary)3 
 
x 
 
 
x 
 
10:00 
17:00  
 
x 
 
 
 
 
12:00 
19:00 Dinner (voluntary)3 
Discharge from trial site7 
 
x 
 
 
x 
 
2 
24:00 
08:00 Ambulatory visit 
x 
x 
 
 
 
x 
3 
48:00 
08:00 Ambulatory visit 
 
x 
 
 
 
x 
4 
72:00 
08:00 Ambulatory visit 
 
x 
 
 
 
x 
FU 
4 
4 to 14 
 
  End of trial (EoTrial) examination4 
x 
 
x 
 
x 
x 
 
1. 
Subject must be informed and written informed consent obtained prior to starting any screening procedures. Screening 
procedures include physical examination, check of vital signs, ECG, safety laboratory (including drug screening), 
demographics (including determination of body height and weight, smoking status and alcohol history), relevant 
medical history, concomitant therapy and review of inclusion/exclusion criteria.  
2. 
The time is approximate; the procedure is to be performed and completed within the 2 h prior to drug administration. 
3. 
If several actions are indicated at the same time, the intake of meals will be the last action. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 9 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
4. 
At the end of trial visit the End of Trial examination includes physical examination, body weight, vital signs, ECG, 
safety laboratory, recording of AEs and concomitant therapies.  
5. 
Only urine drug screening as well as pregnancy test in women will be done at this time. Due to COVID-19 pandemics, 
alcohol breath test is temporarily suspended, and the subject is evaluated clinically by a physician for alcoholic 
ingestion symptoms and signs. 
6. 
AEs and concomitant therapies will be recorded throughout the trial but will be specifically asked for at the times 
indicated in the Flow Chart above. 
7.     After the dinner the subjects will be discharge from the clinical unit.  
 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 10 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
TABLE OF CONTENTS 
TITLE PAGE ......................................................................................................1
CLINICAL TRIAL PROTOCOL SYNOPSIS ................................................2
FLOW CHART ...................................................................................................8
TABLE OF CONTENTS ................................................................................ 10
ABBREVIATIONS .......................................................................................... 14
1. 
INTRODUCTION .................................................................................... 16
1.1
MEDICAL BACKGROUND ............................................................................16
1.2
DRUG PROFILE ...............................................................................................17
1.2.1
Empagliflozin (Empa)...........................................................................17
1.2.2
Metformin (Met) ...................................................................................20
Residual Effect Period ..........................................................................21
1.3
RATIONALE FOR PERFORMING THE TRIAL ........................................21
1.4
BENEFIT - RISK ASSESSMENT ...................................................................21
2. 
TRIAL OBJECTIVES AND ENDPOINTS........................................... 24
2.1
MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS ......24
Main objectives......................................................................................24
Primary endpoints ................................................................................24
Secondary endpoints .............................................................................24
3. 
DESCRIPTION OF DESIGN AND TRIAL POPULATION .............. 25
3.1
OVERALL TRIAL DESIGN AND PLAN ......................................................25
3.2
DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUP ..........................................................................................25
3.3
SELECTION OF TRIAL POPULATION ......................................................26
Main diagnosis for trial entry ..............................................................26
Inclusion criteria ...................................................................................26
Exclusion criteria ..................................................................................26
Withdrawal of subjects from treatment or assessments ...................29
3.3.4.1 Discontinuation of trial treatment ............................................30 
3.3.4.2 Withdrawal of consent to trial participation ............................ 31 
3.3.4.3 Discontinuation of the trial by the sponsor ..............................31 
Replacement of subjects .......................................................................32
If the number of dropouts exceeds that determined in this protocol (> 8), it 
may be considered a complementary group as long as authorized 
by ANVISA. ...........................................................................................32
4. 
TREATMENTS ........................................................................................ 33
4.1
INVESTIGATIONAL TREATMENTS ..........................................................33


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 11 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Identity of the Investigational Medicinal Products ...........................33
Selection of doses in the trial ................................................................34
Method of assigning subjects to treatment groups ............................34
Drug assignment and administration of doses for each subject .......34
Blinding and procedures for unblinding ............................................35
Packaging, labelling, and re-supply ....................................................35
Storage conditions .................................................................................36
Drug accountability ..............................................................................36
4.2
OTHER TREATMENTS, EMERGENCY PROCEDURES, 
RESTRICTIONS ...............................................................................................37
Other treatments and emergency procedures ....................................37
Restrictions ............................................................................................37
4.2.2.1 Restrictions regarding concomitant treatment .........................37 
4.2.2.2 Restrictions on diet and life style .............................................38 
4.3
TREATMENT COMPLIANCE .......................................................................38
5. 
ASSESSMENTS ....................................................................................... 39
5.1
ASSESSMENT OF EFFICACY  Not applicable..............................................39
5.2
ASSESSMENT OF SAFETY ............................................................................39
Physical and clinical examination........................................................39
Vital signs ...............................................................................................40
Safety laboratory parameters ..............................................................40
Electrocardiogram ................................................................................43
Assessment of adverse events ...............................................................44
5.2.5.1 Definitions of adverse events ...................................................44 
 Adverse event ............................................................44 
 Serious adverse event ................................................ 44 
 AEs considered ‘Always Serious’ .............................45 
 Adverse events of special interest .............................45 
 Intensity (severity) of AEs .........................................46 
 Causal relationship of AEs ........................................46 
5.2.5.2 Adverse event collection and reporting ...................................47 
 AE collection ............................................................. 47 
 AE reporting to the sponsor and timelines ................48 
 Information required .................................................. 48 
 Pregnancy ..................................................................48 
5.3
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS ..................................................................................49
Assessment of pharmacokinetics .........................................................49
Methods of sample collection ...............................................................49
5.3.2.1 Blood sampling for pharmacokinetic analysis ......................... 49 
6. 
STUDY PROCEEDINGS……………………………………50 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 12 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
6.1
SITE AND FORM OF CONFINEMENT ........................................................50
Site ..........................................................................................................50
Form of confinement of the search participant ..................................50
6.2
BIOSAFETY PROCEDURES DUE TO COVID-19 ..........................................50
6.3
UNITARIZATION ............................................................................................52
6.4
FASTING AND FEEDING TIMES .................................................................52
6.5
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS ..................................................................................54
Assessment of pharmacokinetics .........................................................54
Methods of sample collection ...............................................................54
6.5.2.1 Blood sampling for pharmacokinetic analysis ......................... 54 
Procedures for the handling and storage of biological samples .......57
6.5.3.1 Internal transportation of biological samples ........................... 57 
6.5.3.2 Identification of the samples .................................................... 57 
6.5.3.3 Handling, storage and transportation .......................................57 
Analytical determinations ....................................................................59
6.5.4.1 Analytical determination of analyte plasma concentration ...... 59 
6.6
ASSESSMENT OF BIOMARKER(S) .............................................................59
6.7
BIOBANKING ...................................................................................................59
6.8
OTHER ASSESSMENTS .................................................................................59
6.9
APPROPRIATENESS OF MEASUREMENTS .............................................60
7. 
INVESTIGATIONAL PLAN .................................................................. 61
7.1
VISIT SCHEDULE ............................................................................................61
7.2
IF A SUBJECT MISSES AN APPOINTMENT, IT WILL BE 
RESCHEDULED IF POSSIBLE. DETAILS OF TRIAL PROCEDURES 
AT SELECTED VISITS ....................................................................................61
Screening ................................................................................................61
Treatment periods .................................................................................61
8. 
STATISTICAL METHODS AND DETERMINATION OF 
SAMPLE SIZE ......................................................................................... 62
8.1
STATISTICAL DESIGN – MODEL ...............................................................62
8.2
NULL AND ALTERNATIVE HYPOTHESES ..............................................63
8.3
PLANNED ANALYSES ....................................................................................63
Primary and key secondary endpoint analyses ..................................64
8.4
I
8.5
HANDLING OF MISSING DATA ..................................................................66


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 13 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Safety ......................................................................................................66
Pharmacokinetics ..................................................................................66
8.6
RANDOMISATION ..........................................................................................66
8.7
DETERMINATION OF SAMPLE SIZE ........................................................67
The sample size for this trial was determined using assumptions on the intra-
individual variability of the primary endpoints based on previous studies -
performed at 
 For both actives, empagliflozin and metformin,Cmax the 
geometric coefficient of variation (gCV) was estimated to be between 9% and 
23%, while for AUC the gCV was between 9% and 23%. ..................................67
9. 
INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND 
ADMINISTRATIVE STRUCTURE ...................................................... 68
9.1
TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED 
CONSENT ..........................................................................................................68
9.2
DATA QUALITY ASSURANCE .....................................................................69
9.3
RECORDS ..........................................................................................................69
Source documents .................................................................................69
Direct access to source data and documents.......................................70
Storage period of records.....................................................................70
9.4
EXPEDITED REPORTING OF ADVERSE EVENTS .................................71
9.5
STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY .......71
Collection, storage and future use of biological samples and 
corresponding data ...............................................................................71
9.6
TRIAL MILESTONES .....................................................................................71
9.7
ADMINISTRATIVE STRUCTURE OF THE TRIAL ..................................72
10. REFERENCES ......................................................................................... 73
10.1
PUBLISHED REFERENCES ...........................................................................73
10.2
UNPUBLISHED REFERENCES .....................................................................73
c01678844-16     Empagliflozin Investigator’s Brochure ................................. 73
BI-KMED-PV-CLT-0015    POTENTIAL DRUG-INDUCED 
LIVER INJURY (DILI) CHECKLIST APPENDICES ....................... 74
11. DESCRIPTION OF GLOBAL AMENDMENT(S) .............................. 75
11.1
GLOBAL AMENDMENT 1 .............................................................................75
11.2
GLOBAL AMENDMENT 2 .............................................................................75


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 14 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
ABBREVIATIONS 
AE 
Adverse event 
  
Aet1-t2 
Amount of analyte eliminated in urine over the time interval from t1 to t2. 
  
AMG 
Arzneimittelgesetz (German drug law) 
  
ANOVA 
Analysis of variance 
  
ANVISA 
AUC0-∞ 
Agência Nacional de Vigilância Sanitária (in Portuguese) 
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 interpolated to infinity 
  
 
 
  
AUC0-tz 
Area under the concentration-time curve of the analyte in plasma over the 
time interval from 0 to the last quantifiable data point 
  
BA 
Bioavailability 
  
BI 
Boehringer Ingelheim 
  
BID 
Bis in die (twice daily) 
  
BLQ 
Below limit of quantification 
  
BMI 
Body mass index (weight divided by height squared) 
  
BP 
Blood pressure 
  
CA 
Competent authority 
  
CI 
Confidence interval 
  
CL/F 
Apparent clearance of the analyte in plasma after extravascular 
administration 
  
Cmax 
Maximum measured concentration of the analyte in plasma 
  
CTMF 
Clinical trial master file 
  
CTP 
Clinical trial protocol 
  
CTR 
Clinical trial report 
  
CV 
Arithmetic coefficient of variation 
  
DILI 
Drug-induced liver injury 
  
ECG 
Electrocardiogram 
  
eCRF 
Electronic case report form 
  
EDTA 
Ethylenediaminetetraacetic acid 
  
EOT 
End of trial 
  
F 
Absolute bioavailability factor 
  
FDC 
Fixed dose combination 
  
gCV 
Geometric coefficient of variation 
  
gMean 
Geometric mean 
  
  
HPLC-MS/MS 
High performance liquid chromatography with tandem mass spectrometry 
  
IB 
Investigator’s brochure 
  
IEC 
Independent Ethics Committee 
  
IRB 
Institutional Review Board 
  
ISF 
Investigator site file 
  
λz 
Terminal rate constant of the analyte in plasma 
  
MedDRA 
Medical Dictionary for Regulatory Activities 
  


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 15 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
 
  
 
 
  
MRTpo 
Mean residence time of the analyte in the body after oral administration 
  
NC 
Not calculated 
  
NOA 
Not analysed 
  
NOAEL 
No observed adverse effect level 
  
NOP 
No peak detectable 
  
NOR 
No valid result 
  
NOS 
No sample available 
  
PK 
Pharmacokinetic(s) 
  
PKS 
Pharmacokinetic set 
  
PR 
Pulse rate 
  
R 
Reference treatment 
  
SAE 
Serious adverse event 
  
SCR 
Screening 
  
SGLT(-1/2) 
Sodium-glucose-transporter (1/2) 
  
SmPC 
Summary of Product Characteristics 
  
ss 
(at) steady state 
  
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
  
T 
Test product or treatment 
  
t1/2 
Terminal half-life of the analyte in plasma = HL_Lambda 
  
tmax 
Time from (last) dosing to the maximum measured concentration of the 
analyte in plasma 
  
tz 
Time of last measurable concentration of the analyte in plasma 
  
T2DM 
Type 2 diabetes mellitus 
  
TDMAP 
Trial Data Management and Analysis Plan 
  
TSAP 
Trial statistical analysis plan 
  
Vz 
Apparent volume of distribution during the terminal phase λz after 
intravascular administration 
  
Vz/F 
Apparent volume of distribution during the terminal phase λz after 
extravascular administration 
  


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 16 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
1. 
INTRODUCTION 
Empagliflozin (BI 10773) is an orally available inhibitor of the sodium-glucose co-
transporter 2 (SGLT-2), that promotes enhanced glucose excretion in the urine, thereby 
lowering blood glucose concentrations in patients with type 2 diabetes mellitus (T2DM). 
Metformin (Met) is an oral antihyperglycemic agent that reduces plasma glucose levels by 
decreasing intestinal glucose absorption and hepatic glucose production and enhancing the 
glucose uptake and utilization of peripheral tissue.  
1.1 
MEDICAL BACKGROUND 
Type 2 diabetes mellitus accounts for 90 to 95% of all cases of diabetes and is an increasingly 
prevalent disease with an estimated 415 million affected people worldwide. Complications 
induced by hyperglycaemia are currently the most frequent cause of adult-onset loss of 
vision, renal failure, and amputation in the industrialized world. Diabetes is also associated 
with macrovascular complications with a 2- to 4-fold increase in cardiovascular disease risk. 
The high frequency of complications leads to a significant reduction of life expectancy. 
Currently available oral antidiabetic drugs are efficacious, but still fail to achieve an optimal 
blood glucose control in many patients. 
SGLT-2 is a member of a larger group of sodium substrate co-transporters, the sodium-
glucose co-transport 5 (SLC5) gene family [R05-0939]. Under normoglycemia, glucose is 
almost completely reabsorbed by SGLTs in the kidney, whereas the reuptake capacity of the 
kidney is saturated at plasma glucose concentrations higher than approximately 10-11 
mmol/L, resulting in increasing glucosuria typically seen in patients with diabetes mellitus. 
The capacity to reabsorb glucose can be decreased by inhibition of SGLT-2. In humans, 
empagliflozin very selectively blocks glucose transport via SGLT-2 (IC50 1.3 nM), with a 
5000-fold selectivity over SGLT-1 (IC50 6278 nM). 
The efficacy of empagliflozin is similar to the current oral antidiabetic drugs and can be 
combined with other oral antidiabetic drugs. Clinical trials demonstrated an additive efficacy 
in terms of glucose control when used in combination with metformin in patients with 
T2DM1,2 (see Section 1.2.1).   
1. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle 
HJ; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients 
with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes 
Care. 2014 Jun;37(6):1650-9. 
2. Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial Combination of 
Empagliflozin and Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2016 
Oct;39(10):1718-28.   
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 17 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
1.2 
DRUG PROFILE 
1.2.1 
Empagliflozin (Empa) 
Non-clinical assessment of safety 
A comprehensive package of safety pharmacology, genetic toxicology, reproductive 
toxicology and general toxicology studies were conducted in mice, rats, rabbits and dogs to 
support the chronic administration of the two empagliflozin doses (10 mg/day and 25 
mg/day) used in phase III clinical trials to humans. The compound was generally well 
tolerated in animals at clinically relevant plasma exposures, while adverse effects were only 
observed at higher doses. Noteworthy adverse findings at effect levels above the NOAEL (no 
observed adverse effect level) in general toxicology studies were body weight loss, lower 
weight gain, dehydration, nephritis and nephropathy. Human clinical exposure at 25 mg/day 
is well below the exposure at the NOAEL of 100 mg/kg/day in male rats after 26 weeks of 
and the NOAEL of 10 mg/kg/day in the dog after 52 weeks of dosing and indicates a 9 to 10 
fold therapeutic window to these NOAEL's.  
In the mouse 2-year carcinogenicity study with empagliflozin a drug-related renal 
adenoma/carcinoma response has been identified in male, but not female mice at 
supratherapeutic doses (highest dose group of 1000 mg/kg/day). In comparison to the 
exposure associated with the 25 mg daily dose in humans, the drug related renal tumours 
occurred in male mice at exposures of approximately 30-fold and were absent at exposures of 
11-fold. No such tumour findings were observed in females at any dose level. Empagliflozin 
is nongenotoxic and the renal tumours in mice appear to result from chronic tubule 
cytotoxicity and cell regeneration. Such epigenetic mechanisms have exposure thresholds, 
below which they are not relevant.   
In a 13-week toxicity study in rats where empagliflozin and metformin were co-administered, 
the NOAEL was considered to be 50 mg/kg/day for empagliflozin and 100 mg/kg/day for 
metformin. There were no new target organs identified when empagliflozin and metformin 
were combined at doses that were tolerable when each compound was dosed alone. These 
data support the safe administration of the combination of empagliflozin (up to 12.5 mg, 
BID) and the marketed compound metformin (up to 1000 mg, BID) to humans. 
Clinical pharmacokinetics 
In humans, empagliflozin predominantly shows linear pharmacokinetics following single oral 
doses and at steady state after multiple oral doses. Empagliflozin was rapidly absorbed 
reaching peak levels at approximately 1.5 h and showed a biphasic decline with the terminal 
elimination half-life ranging from 10 to 19 h. Following oral administration of [14C]-
empagliflozin, approximately 41.2% and 54.4% of drug-related radioactivity was excreted in 
feces and urine, respectively. The majority of drug related radioactivity in plasma was parent 
and the most abundant metabolites were glucuronide conjugates. None of the detected 
metabolites were major as their systemic exposure was less than 10% compared to parent. 
Administration of empagliflozin tablets with a high fat and high calorie meal had no 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 18 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
clinically relevant effect on the overall absorption of empagliflozin. Therefore, empagliflozin 
tablets can be administered with or without food. 
Empagliflozin exposure increased moderately with the extent of renal and hepatic impairment 
suggesting that no dose adjustment is needed. The observations from the phase I study in 
patients with renal impairment indicate a rather low efficacy of empagliflozin in patients with 
severe renal impairment and end-stage renal disease (ESRD), while efficacy is assumed to be 
unchanged with hepatic impairment. 
No clinically relevant pharmacokinetic interactions were observed with metformin, 
glimepiride, sitagliptin, warfarin, linagliptin, verapamil, ramipril, simvastatin, digoxin, 
gemfibrozil and oral contraceptives (Microgynon®). There was a moderate increase in 
pioglitazone exposure in one of two different pioglitazone interaction studies, so that 
monitoring of pioglitazone side effects in patients receiving empagliflozin on top of 
pioglitazone in clinical studies is recommended. 
Clinical efficacy and safety   
Approximately 550 healthy subjects were exposed to empagliflozin (dose range: 0.5 mg to 
800 mg per single dose and up to 50 mg in multiple dosing) in Phase I clinical trials. Of 
these, approximately 240 subjects received multiple doses with empagliflozin 25 mg or 50 
mg once daily. In addition, approximately 240 Caucasian and Japanese patients with T2DM 
were exposed to empagliflozin (10 mg, 25 mg, 50 mg or 100 mg once daily) in phase I 
studies with a duration of 2-4 weeks. In the two completed Phase II studies   approximately 
600 patients with T2DM completed up to 12 weeks of treatment with different doses of 
empagliflozin up to 50 mg once daily. Of these 600 patients, approximately 550 patients 
continued treatment up to an additional 72 weeks. 
Empagliflozin demonstrated good efficacy with approximately 70-90 g/day of urinary 
glucose excretion (UGE), without inducing any significant hypoglycaemia. The twelve week 
Phase II studies demonstrated an HbA1c reduction of up to 0.72 % (placebo subtracted), a 
fasting plasma glucose reduction of up to 32 mg/dL and a weight loss of approximately 1.5 
kg, in both the monotherapy setting and as an add-on to metformin (≥ 1500 mg/day). 
In clinical studies, empagliflozin was well tolerated in both healthy subjects and patients with 
T2DM up to maximal treatment duration of up to 90 weeks in completed studies. Treatment 
with empagliflozin resulted in similar percentage of overall adverse events (AEs) compared 
to placebo and active comparators. Regarding combination therapy of empagliflozin + 
metformin a similar percentage of overall AEs and serious AEs was found in the Phase II 
metformin background therapy trial 1245.10 with 38.5% overall and 2.5 % serious AEs on 
empagliflozin+metformin compared to 36.6% and 2.8% on placebo+metformin. Treatment 
with empagliflozin showed a higher frequency of genital infections and symptoms of 
increased micturition frequency and/or volume, yet was not associated with a higher 
incidence of urinary tract infections or hypoglycaemia.  
A phase III study was designed to evaluate empagliflozin as an add-on therapy to metformin. 
In the with patients with HbA1c levels of ≥7% to ≤ 10% while receiving metformin (≥1,500 
mg/day) were randomized and treated with once-daily treatment with empagliflozin 10 mg (n 
= 217), empagliflozin 25 mg (n = 213), or placebo (n = 207) for 24 weeks. Adverse events 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 19 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
(AEs) were similar across groups (placebo 58.7%; empagliflozin 49.5–57.1%). Confirmed 
hypoglycemic AEs were reported in 0.5%, 1.8%, and 1.4% of patients receiving placebo, 
empagliflozin 10 mg, and empagliflozin 25 mg, respectively. Events consistent with urinary 
tract infections were reported in 4.9%, 5.1%, and 5.6% of patients, and events consistent with 
genital infections were reported in 0%, 3.7%, and 4.7% of patients, respectively. Both 
empagliflozin 10 and 25 mg significantly improved glycaemic control, weight, and BP, and 
were well-tolerated in the 24 weeks period as add-on to metformin therapy1. 
The initial combination of Empa and Met in patients with DM2 was evaluated in a phase III 
clinical trial This study compared the efficacy and safety of initial combinations of 
empagliflozin + metformin with empagliflozin and metformin monotherapy in patients with 
type 2 diabetes. The study randomized 1,364 drug-naïve patients (HbA1c >7.5 to ≤12% [>58 
to ≤108 mmol/mol]) for 24 weeks to empagliflozin 12.5 mg b.i.d. + metformin 1,000 mg 
b.i.d., empagliflozin 12.5 mg b.i.d. + metformin 500 mg b.i.d., empagliflozin 5 mg b.i.d + 
metformin 1,000 mg b.i.d., empagliflozin 5 mg b.i.d. + metformin 500 mg b.i.d., 
empagliflozin 25 mg q.d., empagliflozin 10 mg q.d., metformin 1,000 mg b.i.d., or metformin 
500 mg b.i.d. The primary end point was change from baseline in HbA1c at week 24.At week 
24, reductions in HbA1c (mean baseline 8.6-8.9% [70-73 mmol/mol]) were -1.9 to -2.1% 
with empagliflozin + metformin twice-daily regimens, -1.4% with both empagliflozin once-
daily regimens, and -1.2 to -1.8% with metformin twice-daily regimens. Adverse event (AE) 
rates were similar across groups (56.7-66.3%). No hypoglycemic AEs required assistance. 
The initial combinations of empagliflozin + metformin for 24 weeks significantly reduced 
HbA1c versus empagliflozin once daily and metformin twice daily, without increased 
hypoglycemia, reduced weight versus metformin twice daily, and were well tolerated2. 
1. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle 
HJ; EMPA-REG MET Trial Investigators. Empagliflozin as add-on to metformin in patients 
with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes 
Care. 2014 Jun;37(6):1650-9. 
2. Hadjadj S, Rosenstock J, Meinicke T, Woerle HJ, Broedl UC. Initial Combination of 
Empagliflozin and Metformin in Patients With Type 2 Diabetes. Diabetes Care. 2016 
Oct;39(10):1718-28.   
In summary, empagliflozin was well tolerated in Phase I and Phase II studies in healthy male 
volunteers and patients with T2DM. The vast majority of AEs considered related to 
empagliflozin have been of mild to moderate nature and no deaths have been related to 
empagliflozin. Clinical and non-clinical data support the further development of 
empagliflozin in larger studies with treatment duration of 52 weeks and above. 
Since approval (Fev2015 to Dec2020), approximately 612 726 patient-years with type 2 
diabetes in Brazil have been exposed to Jardiance (and approximately 10 056 876 patient-
years worldwide (April 2014 to April 2020), according to PBRER s00085859-01. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 20 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Worldwide exposure to FDC (Jardiance Duo) has been so far approximately 1 442 835 
patient-years (July 2015 to April 2020) - ref. PBRER s00085859-01. 
The benefit-risk balance of empagliflozin and empagliflozin/metformin remains favourable in 
its authorized indications – ref. PBRER s00085859-01. 
For further details see empagliflozin Investigator’s Brochure [c01678844-16].  
1.2.2 
Metformin (Met) 
Metformin is an oral antihyperglycemic agent that reduces plasma glucose levels by 
decreasing intestinal glucose absorption and hepatic glucose production and enhancing the 
glucose uptake and utilization of peripheral tissue. Thus, metformin renders a reduction of 
basal and postprandial plasma glucose in patients with T2DM. Unlike sulfonylureas (e.g. 
glyburide) metformin does not increase insulin secretion and is not associated with 
hypoglycaemia in either patients with T2DM or healthy volunteers [R11-4761]. 
The absolute bioavailability of metformin is 50-60 % under fasting conditions. The intake of 
food decreases the extent of absorption. A 40% lower Cmax and a 25% lower AUC (area 
under the curve) were reported following a single dose administration of 850 mg metformin 
with food. Studies using single oral doses of 500 – 1500 mg metformin indicate that there is a 
lack of dose proportionality with increasing doses, which is due to decreased absorption 
rather than an alteration in elimination [R10-5341]. 
Metformin is negligibly bound to plasma proteins. The drug partitions into erythrocytes, 
which might represent a deep compartment of distribution. Intravenous studies in healthy 
volunteers demonstrate that metformin is excreted unchanged in the urine and neither 
undergoes hepatic metabolism nor biliary excretion. Following oral administration 
approximately 90% of the absorbed drug is eliminated via the renal route with a plasma-
elimination half-life of about 6.2 hours [R10-5341]. 
Metformin is available as tablets for oral administration in the strengths 500, 850 and 1000 
mg [R10-5341]. The maximum recommended daily dose is 3000 mg in adults [R11-4761]. 
In a double-blind, placebo-controlled US clinical trial involving obese patients with type 2 
diabetes whose hyperglycaemia was not adequately controlled with diet alone, treatment with 
metformin (up to 2550 mg/day) for 29 weeks resulted in significant mean net reductions in 
FPG, PPG and HbA1c of 59 mg/dl, 83 mg/dl, and 1.8 %, respectively, compared to the 
placebo group [R10-5341]. 
Metformin was well tolerated by healthy male volunteers given alone (1000 mg twice daily) 
and in combination with empagliflozin (50 mg once daily) for 5 days [U09-1852-01]. The 
most frequently reported adverse events were headache, diarrhoea and nausea which were 
considered drug related adverse events. The incidence of these events on empagliflozin + 
metformin did not exceed the incidence observed under metformin monotherapy. 
Gastrointestinal side effects such as abdominal pain, diarrhoea and nausea represent well-
known side-effects of metformin [R11-4761]. Hypoglycaemic events did not occur in any 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 21 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
treatment period. The pharmacokinetics of empagliflozin and metformin were similar 
following co-administration compared to both monotherapies alone [U06-1897-08]. 
 
Residual Effect Period 
The Residual Effect Period (REP) of Empa is 4 days. This is the period after the last dose 
with measurable drug levels and/or pharmacodynamic effects is still likely to be present. 
 
The Residual Effect Period (REP) of Met is 3 days. This is the period after the last dose with 
measurable drug levels and/or pharmacodynamic effects is still likely to be present. 
 
1.3 
RATIONALE FOR PERFORMING THE TRIAL 
Combination drug therapy should improve compliance and provide additive glycaemic 
control. This can be achieved by combining drugs with different mechanisms of action which 
work together to have an additive or synergistic antidiabetic effect. Providing both 
ingredients in a single tablet will help facilitate drug dosing and compliance for patients. The 
actual BE study is performed as per local regulatory requirement of ANVISA in Brazil as a 
pre-requisite for local regulatory approval of the empagliflozin/metformin JardianceDuo 
fixed dose combinations.  
1.4 
BENEFIT - RISK ASSESSMENT 
Participation in this bioequivalence study is without any (therapeutic) benefit for healthy 
subjects. Their participation in the study, however, is of major importance for the technical 
validation of the oral fixed dose combination of two antidiabetic principles, empagliflozin 
and metformin. Subjects are exposed to risks of study procedures and risks related to the 
exposure to the trial medication. 
Procedure-related risks
The use of an indwelling venous catheter for the purpose of blood sampling may be 
accompanied by mild bruising and, in rare cases, by transient inflammation of the wall of the 
vein. After initial irritation, the presence of an indwelling cannula is usually painless and 
hardly noticeable. In addition, in rare cases a nerve might be injured while inserting the 
venous catheter, potentially resulting in paraesthesia, reduced sensibility, and/or pain for an 
indefinite period. The same risks apply to venepuncture for blood sampling. 
The total volume of blood withdrawn per patient during the entire study will not exceed 500 
mL.  
Drug-related risks and safety measures 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 22 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Empagliflozin: The overall safety profile of empagliflozin is favourable for human studies at 
chronic doses up to 100 mg/day. The maximum dose administered in the single rising dose 
study was 800 mg and was well tolerated.  
In studies with healthy subjects, the overall adverse event rate with empagliflozin was 32.4%, 
20.3 % with placebo and 24.0% with the comparator groups. One volunteer had a serious 
adverse event (migraine with aura) that required hospitalization, this event was not assessed 
to be drug related. The most frequent adverse events (>2%) comprise headache (12.1 %), 
nasopharyngitis (4.4 %), diarrhea (3.8 %) and nausea (3.1 %). Except for headache (5.1 % in 
placebo) none of these AEs occurred with placebo while various comparators (e.g. 
metformin) had equivalent or greater incidences of these AEs [U06-1897-08]. 
In the present study subjects are exposed to 1 single dose of 10 mg of empagliflozin plus 850 
mg of metformin and 1 single dose of 12,5mg empagliflozin plus 850 mg metformin fixed 
dose combination, which are separated by a wash-out phase of 1 week. Based on the previous 
experience with empagliflozin the safety risk to healthy subjects related to the intake of 
empagliflozin in this trial is expected to be low.  
Metformin: Most frequent adverse events of metformin are [R11-4761]: 
 >10 %:  
gastrointestinal disorders (nausea, vomiting, diarrhoea, stomach ache) 
1-10 %: 
changes in taste 
< 0.01 %: 
skin reactions (erythema, itching, urticaria), abnormal liver function test 
In diabetic patients, the intake of metformin can cause lactic acidosis in very rare cases (< 
0.01%). Risk factors for developing a lactic acidosis are renal insufficiency, impaired hepatic 
function, excessive alcohol intake, vigorous physical activity and heavy fasting. Until now a 
lactic acidosis has not occurred in healthy volunteers. Renal and liver function will be 
checked thoroughly as part of the screening. Alcoholic beverages and unusual physical 
activities are restricted during the study (see Section 4.2.2). 
Gastrointestinal disorders usually occur at the beginning of a metformin therapy. Therefore, 
they are likely to be expected also after single dose administration of metformin in this trial, 
which is in line with the observations in other metformin trials. These adverse events are well 
characterized, disappear within a short period of time and do not represent any safety risk. 
Empagliflozin+Metformin: In a pilot trial the relative bioavailability of a 12.5 mg 
empagliflozin/1000 mg metformin fixed dose combination tablet was compared to the 
respective single tablets in 16 healthy volunteers. The most frequent adverse event was 
diarrhea, which occurred in 6 subjects (mild intensity, drug related in each case). The second 
most frequent reported adverse event was headache (reported by 2 subjects), which was 
assessed to be drug related in one case. No further drug related AEs occurred [U11-1763-01]. 
To compare the pharmacokinetics of FDC tablets of empagliflozin/metformin with individual 
tablets taken together, three randomized, open-label studies were performed with healthy 
subjects received a single FDC tablet of empagliflozin/metformin in one of six dose 
combinations: empagliflozin 5 mg or 12.5 mg and metformin 500 mg, 850 mg or 1,000 mg   
in one period and the individual tablets are taken together under fed conditions in another 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 23 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
period. Bioequivalence was also established under fasted conditions for empagliflozin 12.5 
mg/metformin 1,000 mg FDC versus individual tablets taken together. 
Empagliflozin/metformin FDC tablets were found to be bioequivalent to individual tablets 
taken together at all tested dose strengths and in both fed and fasted conditions1. 
 
1. Rojas C, Link J, Meinicke T, Macha S. Pharmacokinetics of fixed-dose combinations of 
empagliflozin/metformin compared with individual tablets in healthy subjects. Int J Clin 
Pharmacol Ther. 2016 Apr;54(4):282-92.  
 
Although rare, a potential for drug-induced liver injury (DILI) is under constant surveillance 
by sponsors and regulators. Therefore, this trial requires timely detection, evaluation, and 
follow-up of laboratory alterations in selected liver laboratory parameters to ensure subjects´ 
safety; see also section 5.2.6.1.4, adverse events of special interest. 
 
Overall assessment 
In this study two antidiabetic principles are combined. However, neither the use of metformin 
nor of empagliflozin is associated with hypoglycaemic events which can be explained by their 
mode of action. Also, no hypoglycaemic signs and symptoms were observed in previous studies 
investigating the combination of both drugs in healthy subjects. Therefore, a regular 
measurement of blood glucose is not considered necessary during the present study. This will 
be done at any time, if clinical signs or symptoms of hypoglycaemia occur. 
The volunteers in this study receive no direct medical benefit from participation in this study. 
Safety will be ensured by the monitoring of subjects for adverse events clinically and 
verbally. If the investigator should have a clinical concern, the safety of the volunteers will be 
paramount. 
Overall, the risk for subjects participating in this trial is considered to be low and acceptable. 
Because of the anticipated benefit that a successful clinical development of the FDC tablet 
could provide to patients with type 2 diabetes the sponsor feels the benefit of a successful 
clinical development of fixed dose combination tablet to outweigh the risk. 
The total volume of blood withdrawn per subject during the entire study will not exceed the 
volume of a normal blood donation (500 mL). No health-related risk to healthy subjects is 
expected from withdrawal of this volume of blood. 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 24 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
2. 
TRIAL OBJECTIVES AND ENDPOINTS 
2.1
MAIN OBJECTIVES, PRIMARY AND SECONDARY ENDPOINTS
 
Main objectives 
The primary objective of this trial is to establish bioequivalence of the FDC tablets 
(containing 12.5 mg empagliflozin/850 mg metformin) (Test, T) compared with the single 
tablets (10 mg empagliflozin and Glifage® 850 mg tablets) (Reference, R) following oral 
administration.  
 
 
 
Primary endpoints 
The following pharmacokinetic parameters will be determined for empagliflozin and 
metformin:
• Dose-normalized AUC0-tz and Dose-normalized Cmax of empagliflozin  
• AUC0-tz and Cmax of metformin  
 
 
Secondary endpoints 
The following pharmacokinetic parameters will be determined for empagliflozin and 
metformin: 
 
• Dose-normalized AUC0-∞ of empagliflozin 
• AUC0-∞ of metformin  
• Tmax, AUC_%Extrap_obs, HL_Lambda_z and Lambda_z of empagliflozin and 
metformin 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 25 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
3. 
DESCRIPTION OF DESIGN AND TRIAL POPULATION 
3.1 
OVERALL TRIAL DESIGN AND PLAN 
The study will be performed as a randomised, open label, 2x2 crossover trial in healthy male 
and female subjects in order to compare the test treatments (treatment B) to the reference 
treatments (treatment A). The treatments will be: 
Treatment B:   1 FDC tablet 12.5 mg Empa/850 mg metformin (test) 
Treatment A:  1 tablet Empa 10 mg (Reference 1) + 1 tablet Glifage 850 mg (Reference 2) 
The subjects will be randomly allocated to one of the 2 treatment sequences: 
 
Sequence 1 
B A  
Sequence 2 
A B  
 
All treatments will be taken after a high fat high caloric meal. For details refer to Section 4.1. 
In accordance with the resolution RE nº. 1170, the interval between the periods (washout 
period), should be at least seven elimination half-lives of the active ingredient in the blood.  
As such, for empaglifozin and metformin, the wash out period of the study should be at least 
5 days to ensure complete elimination of the drugs.  In this study the two periods will be 
separated by a washout phase of at least 7 days to facilitate operational requirements.  
An overview of all relevant trial activities is provided in the Flow Chart. For visit schedule 
and details of trial procedures at selected visits, refer to Sections 6.1 and 6.2, respectively.  
 
 
3.2 
DISCUSSION OF TRIAL DESIGN, INCLUDING THE CHOICE OF 
CONTROL GROUP 
For bioequivalence trials, the crossover design is preferred because of its efficiency: since 
each subject serves as his/her own control, the comparison between formulations is based on 
an intra-subject comparison, thus removing inter-subject variability from the comparison 
between formulations. This means that the inter-subject variability is removed from the 
comparison between formulations [R94-1529]. 
The open-label treatment is not expected to bias results, since the study endpoints are derived 
from measurement of plasma concentrations of the analyte, which are provided by a 
bioanalytical laboratory that is blinded to treatment allocation. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 26 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
3.3
SELECTION OF TRIAL POPULATION 
It is planned that 32 healthy male and female subjects will enter the study. They will be 
recruited from the volunteers' pool of the 
 trial site. There are no restrictions regarding the 
ethnic group. 
A log of all subjects enrolled into the trial (i.e. who have signed informed consent) will be 
maintained in the ISF irrespective of whether they have been treated with investigational drug 
or not. 
 
Main diagnosis for trial entry 
The study will be performed in healthy subjects. 
 
Inclusion criteria 
Subjects will only be included in the trial if they meet the following criteria: 
1. Healthy male or female subjects according to the assessment of the investigator, as based 
on a complete medical history including a physical examination, vital signs (BP, PR), 12-
lead ECG, and clinical laboratory tests  
 
2. Age of at least 18 (inclusive) to 50 years (inclusive)   
 
3. BMI of 18.5 to 29.9 kg/m2 (inclusive)  
 
4. Signed and dated written informed consent prior to admission to the study, in accordance 
with GCP and local legislation 
5. Male subjects, or female subjects who meet any of the following criteria from at least 30 
days before the first administration of trial medication until 30 days after trial completion: 
- Use of adequate contraception, e.g. any of the following methods plus condom: 
implants, injectables, combined oral or vaginal contraceptives, intrauterine device 
- Sexually abstinent 
- A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)  
-  Surgically sterilised (including hysterectomy) 
 
Exclusion criteria 
Subjects will not be allowed to participate, if any of the following general criteria apply: 
1. Any finding in the medical examination (including BP, PR or ECG) deviating from 
normal and assessed as clinically relevant by the investigator 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 27 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, 
diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the 
range of 50 to 90 bpm  
3. Any laboratory value outside the reference range that the investigator considers to be of 
clinical relevance 
4. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the 
pharmacokinetics of the trial medication (except appendectomy or simple hernia repair) 
5. History of relevant orthostatic hypotension, fainting spells, or blackouts 
6. Chronic or relevant acute infections 
7. Use of drugs within 30 days of planned administration of trial medication that might 
reasonably influence the results of the trial (including drugs that cause QT/QTc interval 
prolongation) 
8. Smoker (more than 5 cigarettes or 1 cigar or 1 pipe per day) 
9. Inability to refrain from smoking on specified trial days 
10. Drug abuse or positive drug screening 
11. Intention to perform excessive physical activities within one week prior to the 
administration of trial medication or during the trial 
12. Inability to comply with the dietary regimen of the trial site 
13. Subject is assessed as unsuitable for inclusion by the investigator, for instance, because 
the subject is not considered able to understand and comply with study requirements, or 
has a condition that would not allow safe participation in the study  
14. Research participants are submitted to surgery or who are hospitalized for any reason 
before the beginning of the study will be carefully evaluated by the physician regarding 
admission to the study, observing an exclusion period that may vary from 4 to 8 weeks; 
15. Positive test for hepatitis B, hepatitis C, or HIV in pre-study tests; 
16. The research participant has AST and/or ALT elevation ≥ 3 times the ULN and a total 
bilirubin elevation ≥ 2 times the ULN (measured in the sample of the same blood) and/or 
needs to be followed up according to a list of DILI verification pending in Investigator's 
File; 
17. The research participant has a known hypersensitivity to the study drug or chemically 
related compounds; 
18. The research participant has participated in any experimental trial or ingested any 
experimental drug within the six months preceding the beginning of this study (ANVISA 
Resolution #34, dated June 3, 2008); 
19. To have used regular medication within 4 weeks previous or 5 half-lives (which have 
longer duration) to the beginning of this study. Only the use of contraceptive pills will be 
allowed to women. The eventual use of medication, that at the Investigator’s or physician 
in charge judgment does not interfere with the study drug pharmacokinetics, will not be 
considered as exclusion criterion; 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 28 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
20. Use of any eventual medication within 07 days prior to the beginning of the study 
treatment, except dipyrone and paracetamol, except for exceptions upon careful and 
justified evaluation by the investigator; 
21. The research participant has a history of alcohol abuse or has ingested alcohol 24 hours 
previous to the hospitalization period; 
22. The research participant has a history of drug abuse [participants using marijuana and 
hashish less than 6 months before the visit will be excluded. For drugs such as cocaine, 
phenicyclidine (PCP), crack and heroin, research participant who presented their use in 
less than 1 year before the visit are excluded]; 
23. Consumption of hepatic metabolism-inducing and/or inhibiting drugs that have a long 
half-life (half-life> 50 hours), fibrate, niacin and cyclosporine, within 30 days before the 
study drug is administered. For those drugs with a half-life of less than 50 hours, the 
clinical investigator will assess case by case, taking into account the drug elimination 
half-life; 
24. Use of monoamine oxidase (MAO) inhibitors (moclobemide, iproniazid, nialamide, 
phenelzine, tranylcypromine) two weeks before the start of treatment; 
25. Use of serotonin reuptake inhibitors (duloxetine, milnacipran, nefazodone, venlafaxine, 
citalopram, escitalopram, fluoxetine, paroxetine, sertraline, fluvoxamine); 
26. The research participant with any psychiatric and/or psychological illness (including 
depression), unless judged clinically not significant by the clinical investigator; 
27. The research participant has a clinically significant history and/or presence of 
gastrointestinal disease (example: chronic diarrhea, intestinal inflammatory disease), 
present gastrointestinal symptoms (example: diarrhea, vomiting), liver or kidney disease, 
or other known condition that may interfere in the absorption, distribution, metabolism or 
excretion of the drug. Research participants with episodes of vomiting within 24 hours 
before the administration of the drug must be evaluated by the clinical investigator 
regarding the possibility of remaining in the study; 
28. The research participant has a clinically significant history or presence of neurological, 
endocrine or pulmonary disease (inclusive a recent history of asthma), hematological, 
immunological, cerebral, metabolic or cardiovascular disease, has hypo or hypertension 
of any etiology which requires pharmacological treatment; has history or clinical case of 
myocardial infarct, angina and/or cardiac insufficiency; 
29. The research participant has donated or lost more than 450mL or more of blood within 
three months previous to the study (Consolidation Ordinance # 05, dated September 28, 
2017); 
30. The research participant has any condition preventing her of participating in the study 
according to the investigator’s judgment; 
31. The research participant is a vegetarian or has dietary habits that preclude ingestion of 
diet offered in the study; 
32. The research participant has the inability to remain seated (approximately 90° plan) for 1 
hour after administration of the drug, or time required at the discretion of the clinical 
investigator; 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 29 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
33. The research participant presents a positive result for the drug test during pre-
hospitalization (Periods 1 or 2); 
34. The research participant consumes vitamins and/or dietary supplements in a period of 07 
days before the beginning of the study; 
35. The research participant consumes food or beverages containing grapefruit within 48 
hours prior to admission to the study and throughout the study period. 
36. Electrocardiographic findings not recommended for participation in the study, at the 
discretion of the investigator; 
37. Research participant who consume more than 05 cups of coffee or tea per day; 
38. Treatment within 3 months prior to the study with any drug with known toxic potential in 
the large organs; 
39. History of serious adverse reactions to any drug; 
40. Positive βHCG test for women; 
41. Breastfeeding women; 
42. Detection or indeterminate / inconclusive result of the SARS-CoV-2 Coronavirus RNA in 
the RT-qPCR exam performed on the day before the admission of each period; 
43. The research participant presents symptoms of COVID-19 infection (even if the result is 
“undetected” in the RT-PCR exam for COVID-19); 
44. Have an average alcohol intake of more than 4 or more doses of alcoholic drinks in a day 
or 8 or more doses of alcoholic drinks per week for women and 5 or more doses of 
alcoholic drinks in a day or 15 or more doses of alcoholic drinks per week for men; 
45. Have donated or lost more than 1500 mL of blood in the past twelve months; 
46. Have done some intense physical exercise in the 24 hours before the hospitalization 
period; 
47. Be unavailable for registration with the CNVB – Brazilian National Register of 
Volunteers in Bioequivalence Studies. 
 
For study restrictions, refer to Section 4.2.2. 
 
Withdrawal of subjects from treatment or assessments 
Subjects may discontinue trial treatment or withdraw consent to trial participation as a whole 
(‘withdrawal of consent’) with very different implications; please see sections 3.3.4.1 and 
3.3.4.2 below. 
If a subject is removed from or withdraws from the trial prior to the first administration of 
trial medication, the data of this subject will not be entered in the case report form (CRF) and 
will not be reported in the clinical trial report (CTR). If a subject is removed from or 
withdraws from the trial after the first administration of trial medication, this will be 
documented and the reason for discontinuation must be recorded in the CRF; in addition, the 
data will be included in the CRF and will be reported in the CTR. At the time of 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 30 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
discontinuation, a complete end of trial examination will be performed, if possible, and the 
information will be recorded in the CRF. If the discontinuation occurs before the end of the 
REP (see Section 1.2.3), the discontinued subject should if possible be questioned for AEs 
and concomitant therapies at or after the end of the REP in order to ensure collection of AEs 
and concomitant therapies throughout the REP, if not contrary to any consent withdrawal of 
the subject. 
If it is known that a subject becomes pregnant during the trial, administration of the trial 
medication is to be stopped immediately, and the subject is to be removed from the trial. The 
subject is to be followed until she has given birth or until the end of the pregnancy. The 
subject’s data are to be collected until the end of the trial (last visit of last subject) and 
reported in the CTR. For reporting of pregnancy and associated events, refer to Section 
5.2.6.2.4.  
3.3.4.1 
Discontinuation of trial treatment 
An individual subject will discontinue trial treatment if: 
1. The subject wants to discontinue trial treatment, without the need to justify the decision 
2. The subject has repeatedly shown to be non-compliant with important trial procedures 
and, in the opinion of both, the investigator and sponsor representative, is not willing or 
able to adhere to the trial requirements in the future. 
3. The subject needs to take concomitant medication that interferes with the investigational 
medicinal product or other trial treatment 
4. The subject can no longer receive trial treatment for medical reasons (such as pregnancy, 
surgery, adverse events [AEs], or diseases) 
5. Chew the tablet while administering the medication; 
6. Study suspension; 
7. The research participant ingests, during the study, some medication that contains the same 
substance that will be used as an internal standard during the analysis of the plasma 
samples; 
8. Ingest during the study, any drug that contains the same substance that will be used as an 
internal standard when analyzing plasma samples; 
9. The participant does not drink 200mL of water while administering the medication; 
10. All cases in which the principal investigator considers the protocol to be flawed and 
which may make the study result questionable (serious adverse reaction or serious 
adverse event, Participant's indiscipline, dietary failure); 
11. Any other condition at the discretion of the responsible researcher / doctor. 
12. Failure to comply with the requirements of the protocol, instructions and restrictions 
related to the study; for example, uncooperative attitude, inability to return to visits and 
improbability to complete the study; 
13. The research participant presents a positive result for the drug test during pre-
hospitalization (Period 1 or 2); 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 31 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
14. The research participant presents during the pre-hospitalization (Period 1 or 2) a positive 
result for the pregnancy test; 
15. Detection or indeterminate / inconclusive result of the SARS-CoV-2 coronavirus RNA in 
the RT-qPCR exam before the admission of each period - (Periods 1 or 2); 
16. The research participant presents symptoms of COVID-19 infection (even if the result 
“Not detected” in the RT-qPCR test) - (Periods 1 or 2); 
17. The subject experienced emesis or diarrhea that occurred at or before two times median 
Tmax of the respective treatment. In this study subjects with an episode of emesis or 
diarrhea within 10 hours after administration should be excluded.  .  
  
In addition to these criteria, the investigator may discontinue subjects at any time based on 
his or her clinical judgment. 
Even if the trial treatment is discontinued, the subject remains in the trial and, given his/her 
agreement, will undergo the procedures for early treatment discontinuation and follow up as 
outlined in the Flow Chart and section 6.2.3. 
3.3.4.2 
Withdrawal of consent to trial participation 
Subjects may withdraw their consent to trial participation at any time without the need to 
justify the decision. If a subject wants to withdraw consent, the investigator should be 
involved in the discussion with the subject and explain the difference between trial treatment 
discontinuation and withdrawal of consent to trial participation, as well as explain the options 
for continued follow up after trial treatment discontinuation, please see section 3.3.4.1 above 
3.3.4.3 
Discontinuation of the trial by the sponsor 
Boehringer Ingelheim reserves the right to discontinue the trial at any time for any of the 
following reasons: 
1. Failure to meet expected enrolment goals overall or at a particular trial site 
2. New toxicological findings, serious adverse events, or any safety information invalidating 
the earlier positive benefit-risk-assessment. More specifically, the trial will be terminated 
if more than 50% of the subjects have drug-related and clinically relevant adverse events 
of moderate or severe intensity, or if at least 1 drug-related serious adverse event is 
reported 
3. Violation of GCP, or the CTP, or the contract with BI impairing the appropriate conduct 
of the trial 
The investigator / trial site will be reimbursed for reasonable expenses incurred in case of 
trial termination (except if item 3 applies). 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 32 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
Replacement of subjects 
Research participants may be replaced in the event of non-compliance with the criteria and 
inclusion and exclusion from the study provided they have not received any of the study 
treatment doses. Replacement subjects should receive the same treatment sequence as those 
who dropped out of a given sequence.  Substitutions are only allowed prior to the 
administration of investigational product.  Subjects who discontinue after drug administration 
are not eligible for replacement. 
 If the number of dropouts exceeds that determined in this protocol (> 8), it may be 
considered a complementary group as long as authorized by ANVISA. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 33 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
4. 
TREATMENTS 
4.1
INVESTIGATIONAL TREATMENTS 
The investigational product is manufactured by 
 
doses will be calculated as a free base of the empagliflozin and as  metformin hydrochloride 
salt. 
 
The molecular weight of Empa is molecular weight is 450.91 g/mol. Empagliflozin is 
administered as free base. The molecular weight of metformin hydrochloride is 165.62 g/mol. 
Metformin is administered as HCl salt and the metformin dose (850 mg) is related to the 
hydrochloride salt. .
 
Identity of the Investigational Medicinal Products 
The characteristics of test product are below: 
Substance: 
 empagliflozin/metformin 
Pharmaceutical formulation: FDC tablet 
Source: 
 
Unit strength: 
12.5 mg empagliflozin, 850 mg metformin HCl 
Posology: 
1-0-0 (single dose in Treatment T only) 
Route of administration: 
p.o. 
The characteristics of reference products are below: 
Substance: 
 empagliflozin 
Pharmaceutical formulation: film-coated tablet 
Source: 
 
Unit strength: 
10 mg empagliflozin 
Posology: 
1-0-0 (single dose in Treatment R only) 
Route of administration: 
p.o. 
 
Substance: 
metformin (Glifage®) 
Pharmaceutical form: 
tablet 
Source: 
 
Unit Strength: 
850 mg metformin HCl 
Posology 
1-0-0 (single dose in Treatment R) 
Route of administration: 
p.o. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 34 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
Selection of doses in the trial  
The dose selected for this trial is one of the standard clinical doses (see Section 1.2). 
 
Method of assigning subjects to treatment groups 
The randomisation list will be provided to the trial site in advance. 
Subjects will be allocated to treatment sequences prior to the first administration of trial 
medication in the morning of Day 1 (Visit 2). For this purpose, numbers of the randomisation 
list will be allocated to the subjects by drawing lots. Subjects are then assigned to a treatment 
sequence according to the randomisation list. 
After the randomization, substitutions are only allowed prior to the administration of 
investigational product (day -1). Replacement subjects should receive the same treatment 
sequence as those who dropped out of a given sequence.   
The randomization list that should be used in the study may be found in Appendix 1. 
The randomisation procedure is described in Section 7.6. 
 
Drug assignment and administration of doses for each 
subject 
This trial is a 2-way crossover study. All subjects will receive the 2 treatments in randomised 
order. The treatments to be evaluated are outlined in Table 4.1.4: 1 below.  
Table 4.1.4: 1 
Dosage and treatment schedule 
Treatment 
Substance 
Formulation 
Unit strength 
Dosage 
Total dose 
T (Test) – 
treatment B 
Empa/Met 
Tablet 
12.5 (Empa)/ 
850 (Met 
HCl) mg 
1 tablet one dose only 
12.5 
(Empa)/ 
850 (Met 
HCl) mg 
R (Reference) 
– treatment A 
Empa 
Tablet 
10 mg Empa 
1 tablet one dose only 
10 mg 
Empa 
 
Met 
Tablet 
850 mg Met 
HCl 
1 tablet one dose only 
850 mg 
Met HCl 
Administration of trial medication will be performed after subjects have fasted overnight; 
fasting is to start no later than 10 h before the scheduled dosing. The investigator (or 
authorised designee) will administer the trial medication as an oral dose together with about 
200 mL of water to subjects who are in a sitting position in 90 degree angle and will stand for 
one hour in this position. For drug administration, the so-called four-eye principle (two-
person rule) should be applied. For this, one authorised employee of the trial site should 
witness the administration of trial medication, and – if applicable – its preparation (e.g. 
reconstitution), if correct dosage cannot be ensured otherwise. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 35 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
In each treatment period, a high-fat, high-calorie meal will be served 30 min before drug 
administration. The subjects must completely consume the meal prior to drug intake. The 
composition of the standard high-fat, high-calorie meal is detailed in Table 4.1.4: 2; this meal 
is in compliance with the ANVISA guidance and drugs label orientation. For restrictions with 
regard to diet, see Section 4.2.2.2. 
Table 4.1.4: 2 
Composition of the high-fat, high-calorie meal 
Ingredients 
kcal 
Strawberry yogurt (300 ml)  
243.00 
Ham and cheese Croissant (2 units) 
489.60 
Buttery sweet donut (1 unit) 
139.00 
Banana (1 unit) 
70.00 
Butter (half soup spoon) 
58.64  
Sum 
1000.24 
Subjects will be kept under close medical surveillance until 12 h after drug administration. 
During the first 1 h after drug administration, subjects are not allowed to lie down (i.e. no 
declination of the upper body of more than 90 degrees from upright posture). 
The treatments will be separated by a wash-out phase of at least 5 days.  
 
Blinding and procedures for unblinding 
This Phase I trial will be handled in an open fashion throughout (that is, during the conduct, 
including data cleaning and preparation of the analysis). This is considered acceptable 
because the potential for bias seems to be low and does not outweigh practical considerations.  
Emergency envelopes will not be provided, because the dose of trial medication is known to 
investigators and subjects.  
PK samples will be labelled in such a way that treatment allocation cannot be derived by the 
analytical site. 
 
Packaging, labelling, and re-supply 
The investigational medicinal products will be provided by 
 
. They will be packaged and labelled in accordance with local law and the 
principles of Good Manufacturing Practice.  
For details of packing and the description of the label, refer to the ISF. 
The telephone number of the sponsor and the name, address and telephone number of the trial 
site are provided in the subject information form. 
No re-supply is planned. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 36 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
Storage conditions 
Drug supplies will be kept in their original packaging and in a secure limited access storage 
area in accordance with the recommended (labelled) storage conditions. If necessary, a 
temperature log must be maintained to make certain that the drug supplies are stored at the 
correct temperature. If the storage conditions are found to be outside the specified range, the 
local clinical monitor (as provided in the list of contacts) is to be contacted immediately. 
The drug supplies will be stored under the responsibility of the 
 until 1 year after the most 
recent product expires. 
 
 
Drug accountability 
The investigator or designee will receive the investigational drugs delivered from the sponsor 
following requirements are fulfilled: 
• Approval of the clinical trial protocol by the IRB / ethics committee 
• Availability of a signed and dated clinical trial contract between the sponsor and the 
investigational site 
• Approval/notification of the regulatory authority, e.g. competent authority 
• Availability of the curriculum vitae of the Principal Investigator 
• Availability of a signed and dated clinical trial protocol   
Only authorised personnel documented in the form 'Trial Staff List' may dispense medication 
to trial subjects. The trial medication must be administered in the manner specified in the 
CTP.  
The investigator or designee must maintain records of the product’s delivery to the trial site, 
the inventory at the site, the use by each subject, and the disposal of unused products.These 
records will include dates, quantities, batch / serial numbers, expiry ('use-by') dates, and the 
unique code numbers assigned to the investigational medicinal product and trial subjects. The 
investigator or designee will maintain records that document adequately that the subjects 
were provided the doses specified by the CTP and reconcile all investigational medicinal 
products received from the sponsor. At the time of disposal of remaining trial medication, the 
investigator or designee must verify that no remaining supplies are in the investigator’s 
possession.  
All unused medication will be disposed of locally by the trial site upon written authorisation 
of the trial clinical monitor. Receipt, usage and disposal of trial medication must be 
documented on the appropriate forms. Account must be given for any discrepancies.


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 37 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
4.2
OTHER TREATMENTS, EMERGENCY PROCEDURES, 
RESTRICTIONS 
 
Other treatments and emergency procedures 
There are no special emergency procedures to be followed. No additional treatment is 
planned. However, if adverse events require treatment, the investigator can authorise 
symptomatic therapy. In those cases, subjects will be treated as necessary and, if required, 
kept under supervision at the trial site or transferred to a hospital until all results of medical 
evaluations are acceptable. 
 is equipped with an emergency room, defibrillators, mobile resuscitation apparat, a 24-
hour ICU ambulance and an ICU bed in major 
 hospital 4 km distant.    
During confinement, in each study period, the participants will be followed by the healthcare 
professionals during all the period viewing the detection of adverse events, including signs of 
toxicity. 
The participants will be instructed about the potential adverse events, as well as the need to 
inform them immediately to the investigator or his/her team.  
Each participant will be requested to report any adverse event symptoms and it has occurred. 
The medical team will also be requested to notify the principal investigator if the use of 
additional medication has been required. 
The questions performed to know if the participant has had some adverse event must be limited 
to general questions, such as: How are you?  
Any adverse events occurring after hospitalization must be immediately informed to the team 
by any mean (telephone, personally, e-mail, etc.). 
 
 
 
Restrictions 
4.2.2.1
Restrictions regarding concomitant treatment 
In principle, no concomitant therapy is allowed. All concomitant or rescue therapies will be 
recorded (including time of intake on study days) on the appropriate pages of the CRF.


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 38 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
4.2.2.2 
Restrictions on diet and life style 
While admitted to the trial site, the subjects will be instructed not to consume any foods or 
drinks other than those provided by the staff. Standardised meals will be served at the times 
indicated in the Flow Chart. No food is allowed for at least 4 h after drug intake. 
From 1 h before drug intake until lunch, fluid intake is restricted to the standard breakfast 
(see Table 4.1.4: 2), the water administered with the drug, and an additional 200 mL of water 
at 2 h and 4 h post-dose (mandatory for all subjects). From lunch until 24 h post-dose, total 
fluid intake is restricted to 3000 mL.  
Alcoholic beverages, grapefruits, Seville oranges (sour or bitter oranges) and their juices, and 
dietary supplements and products containing St. John's wort (Hypericum perforatum) are not 
permitted from 7 days before the first administration of trial medication until after the last PK 
sample of each study period is collected.  
Methylxanthine-containing drinks or foods (such as coffee, tea, cola, energy drinks, or 
chocolate) are not allowed from 24 h before until the last sample collecting. 
Smoking is not allowed during in-house confinement while admitted to the trial site and the 
subject cannot smoke 24 hours before insite registration. 
If female subjects of child-bearing potential are included in the trial, adequate contraception 
is to be maintained throughout the course of the trial (see Section 3.3.2 for the definition of 
adequate measures). 
4.3 
TREATMENT COMPLIANCE 
Compliance will be assured by administration of all trial medication in the study centre under 
supervision of the investigating physician or a designee. The measured plasma concentrations 
of trial medication will provide additional confirmation of compliance. 
Subjects who are non-compliant (for instance, who do not appear for scheduled visits or 
violate trial restrictions) may be removed from the trial and the CRF will be completed 
accordingly (for further procedures, please see Section 3.3.4.1). 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 39 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
5. 
ASSESSMENTS 
5.1
ASSESSMENT OF EFFICACY 
Not applicable.  
5.2 
ASSESSMENT OF SAFETY 
 
Physical and clinical examination 
At screening, the medical examination will include demographics, height and body weight, 
smoking and alcohol history, relevant medical history and concomitant therapy, review of 
inclusion and exclusion criteria, review of vital signs (BP, PR), 12-lead ECG, laboratory 
tests, and a physical examination. At the end of trial examination, it will include review of 
vital signs, 12-lead ECG, laboratory tests, and a physical examination including 
determination of weight. 
In the clinical evaluation, candidates for research participants should not present any obvious 
signs or symptoms of heart, liver, kidney, lung, neurological, gastrointestinal or haematological 
diseases. For such verification, the anamnesis will be carried out, as well as the evaluation of 
the clinical and laboratory exams listed in this protocol.  
During the clinical evaluation, the research participants will be classified according to the racial 
group they belong. To this race classification will be used the auto declaration method, in which 
the participant will auto declare as part of a racial group according to the following definitions: 
white, black, mulatto, yellow or Indian. The physician and/or nurse have to register the declared 
racial group in the clinical evaluation form. 
During the clinical evaluation, the physician should re-investigate any suspicious signs 
and/or symptoms of COVID-19. In case of any suspicions, he should be considered inapt 
and will be guided by the 
 physician to seek external medical care. The research 
participant will receive medical referral from the 
 detailing the signs and symptoms 
of suspected COVID-19 infection. The orientation must be delivered in writing by the 
responsible physician, being signed in two copies by the research participant and by the 
physician. One of the copies must be filed with the medical record of the research participant. 
The Research Participant will only be accepted in the study if they are considered healthy as 
determined by the clinical evaluation and in the laboratory exams done before the beginning of 
the study and if the satisfy the criteria established in items 3.3 and 3.4.  
After proved the state of health, they will be submitted to an interview with the doctor to 
evaluate their mental health, as well as the emotional state to participate in the investigation. 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 40 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
Vital signs 
Systolic and diastolic blood pressures (BP) as well as pulse rate (PR) or heart rate will be 
measured by a blood pressure monitor (
 at the times indicated in the Flow Chart. 
All recordings should be made using the same type of blood pressure recording instrument on 
the same arm, if possible. 
 
Safety laboratory parameters 
For the assessment of laboratory parameters, blood and urine samples will be collected by the 
trial site at the times indicated in the Flow Chart after the subjects have fasted for at least 
10 h. For retests, at the discretion of the investigator or designee, overnight fasting is not 
required.  
The parameters that will be determined are listed in Tables 5.2.3: 1 and 5.2.3: 2. Reference 
ranges will be provided in the ISF, Section 10.  


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 41 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Table 5.2.3: 1 
Routine laboratory tests 
Functional lab group 
Test name [comment/abbreviation] 
A 
B 
Haematology 
Haematocrit 
Haemoglobin 
Red Blood Cell Count/Erythrocytes  
RDW, MCV  
MCH, MCHC 
White Blood Cells/Leucocytes  
Platelet Count/Thrombocytes (quant) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Automatic WBC 
differential, relative  
 
Neutrophils/Leukocytes; Eosinophils/Leukocytes; 
Basophils/ Leukocytes; Monocytes/Leukocytes; 
Lymphocytes/Leukocytes 
Promyelocytes, Blasts  
X 
 
X 
 
Automatic WBC 
differential, absolute  
Neutrophil, absol.; Eosinophils, absol.; Basophils, absol.; 
Monocytes, absol.; Lymphocytes, absol. ; Promyelocytes, 
absol.; Blasts, absol. 
X 
X 
Manual differential 
WBC (if automatic 
differential WBC is 
abnormal) 
Neut. Poly (segs); Neut. Poly (segs), absol.; Neutrophils 
Bands;  Neutrophils Bands, absol.; Eosinophils/Leukocytes; 
Eosinophils, absol.; Basophils/ Leukocytes; Basophils, 
absol.; Monocytes/ Leukocytes; Monocytes, absol.; 
Lymphocytes/Leukocytes; Lymphocytes, absol. 
X 
X 
Hormones 
Beta HCG (for women subjects) 
X 
 
Serologies 
B hepatitis (HBsAg; Anti-HBc IgM) 
C hepatitis 
HIV  
X 
X 
X 
 
Enzymes 
AST [Aspartate transaminase] /GOT, SGOT  
ALT [Alanine transaminase] /GPT, SGPT 
Alkaline Phosphatase 
Gamma-Glutamyl Transferase  
 
X 
X 
X 
X 
 
X 
X 
X 
X 
 
Substrates 
Glucose (Plasma) 
Creatinine  
Bilirubin, Total  
Bilirubin, Direct 
Protein, Total 
Albumin 
Uric Acid  
Cholesterol, total  
Triglyceride 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 42 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Table 5.2.3: 1  
Routine laboratory tests (cont.) 
Functional lab group 
Test name [comment/abbreviation] 
A 
B 
Urinalysis1 (Stix) 
Urine Nitrite (qual) 
Urine Protein (qual) 
Urine Glucose (qual) 
Urine Ketone (qual) 
Urobilinogen (qual) 
Urine Bilirubin (qual) 
Urine RBC/Erythrocytes (qual) 
Urine WBC/Leucocytes (qual) 
Urine ascorbid acid (qual) 
Urine density 
Urine color 
Urine aspect 
Urine pH 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urine sediment1 
(microscopic 
examination)  
Only positive findings will be reported (for instance, the 
presence of sediment bacteria, casts and crystals in sediment, 
squamous epithelial cells, erythrocytes, leukocytes) 
X 
X 
A: parameters to be determined at Visit 1 (screening examination)  
B: parameters to be determined at Visit 3 (end of trial examination) 
 
The tests listed in Table 5.2.3: 2 are exclusionary laboratory tests that may be repeated as 
required. The results will not be entered in the CRF/database and will not be reported in the 
CTR. Except for pregnancy tests and drug screening, it is planned to perform these tests 
during screening only. Pregnancy testing in women will be performed at screening, prior to 
each treatment period, and as part of the end of trial examination. Drug screening will be 
performed at screening and prior to each treatment period. 
Table 5.2.3: 2 
Exclusionary laboratory tests 
Functional lab group 
Test name  
Drug screening (urine) 
Amphetamine/MDA 
Benzodiazepine 
Benzoylecgonine (cocaine)  
Tetrahydrocannabinol 
Morphine1 
Methamphetamines/MDMA/XTC 
Opiates1  
 
Infectious serology (blood) 
 
 
 
Viral analysis 
Hepatitis B surface antigen (qualitative) 
Hepatitis B core antibody (qualitative) 
Hepatitis C antibodies (qualitative) 
HIV-1 and HIV-2 antibody (qualitative) 
 
RT-PCR for SARS-COV-2 at Day -1  
Pregnancy test (urine) 
Beta human chorionic gonadotropin (beta-HCG) 
1. Due to the COVID-19 pandemic and the consequent damage to the supply of inputs in the health area, 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 43 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
the drug detection test can be performed in two different ways, through the kit for detecting seven 
substances [Methamphetamine, Opiates, Morphine, Tetrahydrocannabinol (Marijuana/Marijuana), 
Amphetamine, Benzoylecgonine (Cocaine) and Benzodiazepine] or through the kit for detection of five 
substances [Methamphetamine, Tetrahydrocannabinol (Marijuana/Marijuana), Amphetamine, 
Benzoylecgonine (Cocaine) and Benzodiazepine] added to the evaluation of the use of opium derivatives 
and morphine via specific medical questioning, registered in RQ004 (Clinical evaluation - pre-
hospitalization). 
To encourage compliance with alcoholic restrictions, a clinical evaluation of alcohol 
ingestion will be performed prior to each treatment period, and may be repeated at any time 
during the study at the discretion of an investigator or designee; as per COVID-19 
pandemics, alcohol breath test is temporarily suspended. The results will not be included in 
the CTR. 
The laboratory tests listed in Tables 5.2.3: 1 and 5.2.3: 2 will be performed at
 partner 
analytic laboratory, with the exception of drug screening and pregnancy tests. These tests will 
be performed at the trial site using using Inlab® test (or according availability), respectively, 
or comparable test systems. 
Laboratory data will be transmitted electronically from the laboratory to the trial site. 
 
Electrocardiogram 
Twelve-lead ECGs (I, II, III, aVR, aVL, aVF, V1 - V6) will be recorded using a 
computerised electrocardiograph (
 at the times provided in the Flow Chart.  
To achieve a stable heart rate at rest and to assure high quality recordings, the site personnel 
will be instructed to assure a relaxed and quiet environment, so that all subjects are at 
complete rest. 
All ECGs will be recorded for a 10 sec duration after subjects have rested for at least 5 min in 
a supine position. ECG assessment will always precede all other study procedures scheduled 
for the same time to avoid compromising ECG quality.  
All ECGs will be stored electronically. Electrode placement will be performed according to 
the method of Wilson, Goldberger and Einthoven modified by Mason and Likar (hips and 
shoulders instead of ankles and wrists).  
All locally printed ECGs will be evaluated by the investigator or a designee. Abnormal 
findings will be reported as AEs (during the trial) or baseline conditions (at screening) if 
assessed to be clinically relevant by the investigator. Any ECG abnormalities will be 
carefully monitored and, if necessary, the subject will be removed from the trial and will 
receive the appropriate medical treatment.  
ECGs may be repeated for quality reasons (for instance, due to alternating current artefacts, 
muscle movements, or electrode dislocation) and the repeated ECG will be used for analysis. 
Additional (unscheduled) ECGs may be collected by the investigator for safety reasons.  


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 44 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
Assessment of adverse events 
5.2.5.1
Definitions of adverse events 
Adverse event 
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a medicinal product and which does not necessarily have 
to have a causal relationship with this treatment. 
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
product, whether or not considered related to the medicinal product. 
The following should also be recorded as an AE in the CRF and BI SAE form (if applicable): 
• Worsening of the underlying disease or of other pre-existing conditions  
• Changes in vital signs, ECG, physical examination, and laboratory test results, if they 
are judged clinically relevant by the investigator 
If such abnormalities already pre-exist prior to trial inclusion, they will be considered as 
baseline conditions and should be collected in the eCRF only. 
Serious adverse event 
A serious adverse event (SAE) is defined as any AE which fulfils at least one of the 
following criteria:
• Results in death  
• Is life-threatening, which refers to an event in which the patient was at risk of death 
at the time of the event; it does not refer to an event that hypothetically might have 
caused death if more severe  
• Requires inpatient hospitalisation    
• Requires prolongation of existing hospitalisation 
• Results in persistent or significant disability or incapacity  
• Is a congenital anomaly/birth defect  
• Is deemed serious for any other reason if it is an important medical event when based 
upon appropriate medical judgment which may jeopardize the patient and may 
require medical or surgical intervention to prevent one of the other outcomes listed in 
the above definitions. Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalization or development of dependency or 
abuse  


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 45 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
AEs considered ‘Always Serious’ 
Cancers of new histology and exacerbations of existing cancer must be classified as a serious 
event regardless of the time since discontinuation of the trial medication and must be reported 
as described in 5.2.6.2, subsections ‘AE Collection’ and ‘AE reporting to sponsor and 
timelines’. 
In accordance with the European Medicines Agency initiative on Important Medical Events, 
Boehringer Ingelheim has set up a list of further AEs, which, by their nature, can always be 
considered to be ‘serious’ even though they may not have met the criteria of an SAE as 
defined above. 
A copy of the latest list of ‘Always Serious AEs’ will be provided upon request. These events 
should always be reported as SAEs as described above. 
Adverse events of special interest 
The term adverse events of special interest (AESI) relates to any specific AE that has been 
identified at the project level as being of particular concern for prospective safety monitoring 
and safety assessment within this trial, e.g. the potential for AEs based on knowledge from 
other compounds in the same class. AESIs need to be reported to the sponsor’s 
Pharmacovigilance Department within the same timeframe that applies to SAEs, please see 
section 5.2.6.2.2. 
Hepatic injury
A hepatic injury is defined by the following alterations of hepatic laboratory parameters after 
randomisation: 
• an elevation of AST and/or ALT ≥ 3 fold ULN combined with an elevation of total bilirubin 
> 2 fold ULN measured in the same blood draw sample, and/or 
• isolated elevation of ALT and/or AST ≥ 5 fold ULN. 
 
These laboratory findings constitute a hepatic injury alert and the patients showing these 
laboratory abnormalities need to be followed up according to the “DILI checklist” provided. 
In case of clinical symptoms of hepatic injury (icterus, unexplained encephalopathy, 
unexplained coagulopathy, right upper quadrant abdominal pain, etc.) without lab results 
(ALT, AST, total bilirubin) available, the investigator should make sure these parameters are 
analysed, if necessary in an unscheduled blood test. Should the results meet the criteria of 
hepatic injury alert, the procedures described in the “DILI checklist” should be followed. [BI-
KMED-PV-CLT-0015]. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 46 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Intensity (severity) of AEs 
The intensity (severity) of the AE should be judged based on the following: 
Mild:  
Awareness of sign(s) or symptom(s) that is/are easily tolerated 
Moderate: 
Sufficient discomfort to cause interference with usual activity 
Severe: 
Incapacitating or causing inability to work or to perform usual activities 
Causal relationship of AEs 
Medical judgment should be used to determine the relationship, considering all relevant 
factors, including pattern of reaction, temporal relationship, de-challenge or re-challenge, 
confounding factors such as concomitant medication, concomitant diseases and relevant 
history. 
Arguments that may suggest that there is a reasonable possibility of a causal relationship 
could be: 
• The event is consistent with the known pharmacology of the drug  
• The event is known to be caused by or attributed to the drug class 
• A plausible time to onset of the event relative to the time of drug exposure 
• Evidence that the event is reproducible when the drug is re-introduced 
• No medically sound alternative aetiologies that could explain the event (e.g. pre-
existing or concomitant diseases, or co-medications) 
• The event is typically drug-related and infrequent in the general population not 
exposed to drugs (e.g. Stevens-Johnson syndrome) 
• An indication of dose-response (i.e. greater effect size if the dose is increased, smaller 
effect size if dose is reduced) 
Arguments that may suggest that there is no reasonable possibility of a causal relationship 
could be: 
• No plausible time to onset of the event relative to the time of drug exposure is evident 
(e.g. pre-treatment cases, diagnosis of cancer or chronic disease within days / weeks 
of drug administration; an allergic reaction weeks after discontinuation of the drug 
concerned) 
• Continuation of the event despite the withdrawal of the medication, considering the 
pharmacological properties of the compound (e.g. after 5 half-lives). Of note, this 
criterion may not be applicable to events whose time course is prolonged despite 
removing the original trigger 
• Additional arguments amongst those stated before, like alternative explanation (e.g. 
situations where other drugs or underlying diseases appear to provide a more likely 
explanation for the observed event than the drug concerned) 
• Disappearance of the event even though the trial drug treatment continues or remains 
unchanged  


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 47 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
5.2.5.2
Adverse event collection and reporting 
AE collection
Upon enrolment into a trial, the subject’s baseline condition is assessed (for instance, by 
documentation of medical history/concomitant diagnoses), and relevant changes from 
baseline are noted subsequently.  
Subjects will be required to report spontaneously any AEs as well as the time of onset, end 
time, and intensity of these events. In addition, each subject will be regularly assessed by the 
medical staff throughout the clinical trial and whenever the investigator deems necessary. As 
a minimum, subjects will be questioned for AEs (and concomitant therapies) at the time 
points indicated in the Flow Chart. Assessment will be made using non-specific questions 
such as ‘How do you feel?’. Specific questions will be asked wherever necessary in order to 
more precisely describe an AE. 
A carefully written record of all AEs shall be kept by the investigator in charge of the trial. 
Records of AEs shall include data on the time of onset, end time, intensity of the event, and 
any treatment or action required for the event and its outcome. 
The following must be collected and documented on the appropriate CRF(s) by the 
investigator:
• From signing the informed consent onwards until an individual subject’s end of trial:  
o All AEs (serious and non-serious) and all AESIs  
o The only exception to this rule are AEs (serious and non-serious) and AESIs 
in Phase I trials in healthy volunteers, when subjects discontinue from the trial 
due to screening failures prior to administration of any trial medication. In 
these cases, the subjects’ data must be collected at trial site but will not be 
entered in the CRF or trial database and will not be reported in the CTR. 
• After the individual subject’s end of trial:  
o The investigator does not need to actively monitor the subject for AEs but 
should only report any occurrence of cancer and related SAEs and related 
AESIs of which the investigator may become aware of by any means of 
communication, e.g. phone call. Those AEs should, however, not be reported 
in the CRF. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 48 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
AE reporting to the sponsor and timelines 
The Investigator must report SAEs, AESIs, and non-serious AEs which are relevant for the 
reported SAE or AESI, on the BI SAE form via fax immediately (within 24 hours) to the 
sponsor’s unique entry point. The same timeline applies if follow-up information becomes 
available. In specific occasions the Investigator could inform the sponsor upfront via 
telephone. This does not replace the requirement to complete and fax the BI SAE form.  
The contact information is: 
 
Pharmacovigilance and Customer Service 
 
 
Tel.: 
 
Cel: 
 
Fax.:
 
 
The toll-free 
 and the
 e-
mail can also be used for communications. 
 
With receipt of any further information to these events, a follow-up SAE form has to be 
provided. For follow-up information, the same rules and timeline apply as for initial 
information. 
Information required 
All (S)AEs, including those persisting after the individual subject’s end of trial, must be 
followed up until they have resolved, have been sufficiently assessed as ‘chronic’ or ‘stable’, 
or no further information can be obtained. 
Pregnancy 
In rare cases, pregnancy might occur in a clinical trial. Once a subject has been enrolled in 
the clinical trial and has taken trial medication, the investigator must report any drug 
exposure during pregnancy in a trial participant immediately (within 24 hours) by means of 
Part A of the Pregnancy Monitoring Form to the sponsor’s unique entry point. 
The outcome of the pregnancy associated with the drug exposure during pregnancy must be 
followed up and reported to the sponsor’s unique entry point on the Pregnancy Monitoring 
Form for Clinical Trials (Part B). 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 49 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
The ISF will contain the Pregnancy Monitoring Form for Clinical Trials (Part A and Part B) 
as well as non-trial specific information and consent for the pregnant partner. 
As pregnancy itself is not to be reported as an AE, in the absence of an accompanying SAE 
and/or AESI, only the Pregnancy Monitoring Form for Clinical Trials and not the SAE form 
is to be completed. If there is an SAE and/or AESI associated with the pregnancy, an SAE 
form must be completed in addition. 
5.3
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS 
 
Assessment of pharmacokinetics 
For the assessment of pharmacokinetics, blood samples will be collected at the time points 
indicated in the Flow Chart. The actual sampling times will be recorded and used for 
determination of pharmacokinetic parameters.  
 
Methods of sample collection 
5.3.2.1
Blood sampling for pharmacokinetic analysis 
For quantification of analyte concentrations in plasma, 8 mL of blood will be drawn from an 
antecubital or forearm vein into an anticoagulant blood drawing tube at the times indicated in 
the Flow Chart. Blood will be withdrawn by means of either an indwelling venous catheter or 
by venepuncture with a metal needle. 
The EDTA-anticoagulated blood samples will be centrifuged within 45 minutes after 
collection while stored in an ice water bath. The samples will be centrifuged for 
approximately 10 min at approximately 2000 g to 4000 g and at 4 to 8 °C. Four plasma 
aliquots will be obtained and stored in polypropylene tubes. Each  aliquot should contain at 
least 0.5 mL of plasma. The process from blood collection until transfer of plasma aliquots 
into the freezer should be completed in less than 60 min, with interim storage of blood 
samples and aliquots in ice water or on ice. The time each aliquot was placed in the freezer 
will be documented. Until transfer on dry ice to the analytical laboratory, the aliquots will be 
stored upright at approximately -20°C or below at the trial site. 
The third and fourth aliquot will be transferred to the analytical laboratory after the bioanalyst 
has acknowledged safe arrival of the first and second aliquot. At the analytical laboratory, the 
plasma samples will be stored at approximately -20°C or below until analysis. 
Empagliflozin and Metformin concentrations may be measured either by use of the same or 
different aliquots. 
At a minimum, the sample tube labels should list BI trial number, subject number, visit, and 
planned sampling time.  
Plasma samples will be discarded at latest 6 months after the final clinical trial report has 
been signed. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 50 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
6. 
STUDY PROCEEDINGS 
6.1
 SITE AND FORM OF CONFINEMENT 
 
Site 
Clinical Site: 
. 
Address:
 
 
Phone: 
 
 
 
Form of confinement of the search participant 
The healthy research participants will remain confined in the premises of cinical unit of 
, under the responsibility of the medical team and under the 
care of the nursing team.  
Due to the COVID-19 pandemic, research participants will have to attend 
staggered without agglomeration. Therefore, the day before the administration of the 
drug, research participants must attend the 
 on a staggered basis 
from 5 pm. 
 
On the day of drug administration, the nursing professional will start the routine procedures 
predicted for the participant during confinement including measurement of systolic blood 
pressure, diastolic blood pressure, heart rate and temperature. The pharmacist in charge will 
release the medication following the list of randomization contained in the Annex 2, also 
providing to the nursing professional and the team involved in the collection of blood samples, 
the instructions related to the protocol. Therefore, the phlebotomists will install the heparinized 
intravenous catheters to perform the collections of sample zero (pre-dose) and those predicted 
throughout the day. The staff in charge for the collection will remain at the confinement site 
throughout hospitalization. There will be frequent visits of the nursing team to the bed where 
each participant is kept during the entire hospitalization period. 
 
6.2 
BIOSAFETY PROCEDURES DUE TO COVID-19  
The World Health Organization (WHO) declared, on January 30, 2020, that the outbreak of the 
disease caused by the new coronavirus (COVID-19) constitutes a Public Health Emergency of 
International Importance - the Organization's highest alert level, as provided for in the 
International Health Regulations. On March 11, 2020, COVID-19 was characterized by WHO 
as a pandemic. For this reason, hospitalizations of research participants must follow strict 
biosafety criteria. According to POP "COVID-19-001 - Measures for the prevention and 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 51 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
control of environments and people in the clinical unit during the COVID-19 pandemic", the 
admission of research participants should be carried out without agglomeration. Therefore, the 
entrance of the participants will be carried out in a staggered manner and will take place in a 
reception separate from the main building. 
Also at the entrance before entering the unit (that is, at the unit door), a questionnaire on 
symptoms of COVID-19 infection will be carried out. 
The following procedures must be followed: 
1. At the entrance of the 
, the research participants will be asked regarding specific 
symptoms for COVID-19 infection (pre-screening):  
 
a. Do you have or have you had a fever in the last 14 days? 
(  )YES  (  ) NO 
b. Do you have or have you had any signs and/or symptoms of flu in the last 14 days? 
(  )YES  (  ) NO 
c. Do you have or have you had difficulty breathing in the last 14 days? 
(  )YES  (  ) NO 
d. Do you have or have you had a cough in the last 14 days? 
(  )YES  (  ) NO 
e. Do you have or have you had a sore throat in the last 14 days? 
(  )YES  (  ) NO 
f. Did you have contact with any person suspected or confirmed of infection with 
new coronavirus? 
(  )YES  (  ) NO 
g. Do you have changes in taste and/or smell? 
(  )YES  (  ) NO 
h. Have you had vomiting or diarrhoea in the last 14 days? 
(  )YES  (  ) NO 
i. Temperature: ____°C 
 
2. The temperature of the research participants must be checked by a non-contact infrared 
thermometer. The temperature must be below or equal to 37 ° C; 
3. If the research participant answers YES to any of the questions or has a temperature above 
37ºC he/she cannot enter the 
 facilities and must be instructed by the 
 medical team to 
seek medical assistance outside the 
. The guidance must be writing by the 
 responsible 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 52 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
physician, and must be signed in two copies by the research participant and the physician. One 
of the copies must be filed with the research participant's medical record. 
4. All research participants must disinfect their hands with 70% alcohol before entering the 
 
facilities. Every 2 hours the nursing team must request that the research participants wash their 
hands with soap and water and then disinfect with 70% alcohol. During sleep times, research 
participants may remain with a longer interval between sanitizations. 
5. Disposable masks must be made available and they must be changed every 2 hours. Research 
participants must wear the masks for the entire period they are on the
 premises; 
6. Participants must hand over their personal belongings to the nursing staff and after 
disinfection with 70% alcohol or another disinfectant product, they will be placed in a sealed 
plastic bag and stored in a specific place and will be returned at the time of discharge from 
hospital. 
7. Research participants must go to the nursing area and immediately take a shower (including 
hair) and change clothes (clothing provided by 
); 
8. The clothes of each participant will be placed in a sealed plastic bag and allocated with their 
personal objects that will be returned at the time of discharge from hospital. 
9. The entire environment should be kept ventilated with the opening of the windows, if 
possible. In the event of natural phenomena, such as rain, the windows may be closed; 
10. All meals will be carried out on the bed in previously disinfected and disposable containers 
(including cutlery and glasses). 
6.3 
UNITARIZATION 
The study drugs will be unified according to POP CLIN 016 (Preparation and Administration 
of Medicines). 
After receiving the drugs in study, the date on which the unitarization will take place will be 
defined, this may happen before the day of medication administration (blistered drugs) or on 
the day of medication administration (un-blistered drugs). 
 
The dosage will be performed according Section 4.1.4.  
 
6.4 
FASTING AND FEEDING TIMES 
The night before drug administration the research participant will go to the Clinical Unit of 
 and must have their last meal until 08.30 p.m., and they 
will remain in fast of at least 10 hours, subjects will receive a standardized high fat breakfast 
at approximately 06:30AM. Breakfast must be consumed within 25-30 minutes.   
In order to maintain the standardization of the treatment groups, the diet (food and liquids) to 
be provided will follow the same standard, in all periods of confinement, for all research 
participants and must be free of fried and fat foods. To plan the menu, the nutrition professional 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 53 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
will use as caloric reference the established in Ordinance nº 193 dated 12/5/2006, article 5, 
paragraph 3 of the Worker Feeding Program (“PAT”). This way the meals provided will follow 
the following caloric quantities: 
 
• Breakfast (before dose): must contain approximately 1000 calories; 
• Main meals (lunch and dinner): must contain from 684 to 930 calories;  
• Minor meals (snack): must contain from 200 to 400 calories; 
• Minor meals (breakfast in extra collections): must contain from 170 to 200 calories. 
 
The person in charge for the clinical step will provide the instructions to the Nutrition Service 
about the standardized diet that will be provided to the healthy research participant, also 
highlighting the prohibition of the intake of beverages or foods containing caffeine or xanthines 
(black and mate tea, coffee, cocoa milk, cola sodas, guaraná, foods containing chocolate and 
others). The composition of the meals is on Appendix 3.  
 
Meal times 
• Dinner – minimum of 10 hours of fasting; 
• Breakfast – 30 minutes before the administration of the drug; 
• Lunch – 4 hours after the administration of the drug; 
• Snack - 8 hours after the administration of the drug; 
• Dinner – 10 hours after the administration of the drug. 
 
Liquids 
• Allowed at ease – until 7 hours before the administration of the drug and after two hours 
of the administration of the drug;  
• During the breakfast – 300 mL of yogurt; 
• Prohibited ingestion of liquids – from 7 hours before the administration of the drug until 
two hours after the administration of the drug, except 300 mL of yogurt during the 
breakfast and 200 mL of water during the drug administration.  
 
 
 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 54 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
6.5
DRUG CONCENTRATION MEASUREMENTS AND 
PHARMACOKINETICS 
 
Assessment of pharmacokinetics 
For the assessment of pharmacokinetics, blood samples will be collected at the time points 
indicated in the Flow Chart. The actual sampling times will be recorded and used for 
determination of pharmacokinetic parameters.  
 
Methods of sample collection 
6.5.2.1
Blood sampling for pharmacokinetic analysis 
For quantification of analyte concentrations in plasma, 8  mL of blood will be drawn from an 
antecubital or forearm vein into an tube K2-EDTA (dipotassium ethylenediaminetetraacetic 
acid)-anticoagulant blood drawing tube at the times indicated in the Flow Chart.  
The first 22 collections (pre-dose + 21 pharmacokinetic samples) will be performed through a 
heparinized intravenous catheter introduced in superficial vein of the research participant. The 
other collections will be carried out by means of direct venipuncture. 
 
If there is any difficulty in intravenous collection due to catheter block, blood will be collected 
by means of direct puncture or a new intravenous catheter will be inserted into the research 
participant.  
After each blood collection performed through the intravenous catheter, it will be washed with 
0.5mL of sodium heparin solution to prevent catheter blockage. Therefore, before each 
collection performed through the intravenous catheter, 0.5mL of blood will be drawn and the 
same will be discarded. 
 
The pre-dose collection (collection 1) will be carried out before the medication is administered. 
In total, 1 sample of 15mL of blood will be collected to perform the pre-study exams), 50 blood 
samples of 8 mL for PK, 44 blood samples of 0.5mL for washing the catheter and 1 blood 
sample of 15 mL to perform the post-study exams. The total blood volume is described in Table 
6.5.2.1: 1. 
 
Table 6.5.2.1: 1– Amount of blood to be collected. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 55 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Sample type 
Blood 
volume 
(mL) 
Number of collections 
Total 
volume 
(mL) 
Pre-study 
exams 
During the 
study 
Post-study 
exams 
Laboratory 
tests 
15 mL 
1 
NA 
1 
30 mL 
Pharmacokinetic 
samples 
8 mL 
NA 
50 
NA 
400 mL 
Discarded 
blood* 
0,5 mL 
NA 
44 
NA 
22 mL 
Total 
 
452 mL 
*Before each collection, (up to the 12-hour collection) approximately 0.5 mL of blood will be discarded in order 
to remove the heparin solution used for washing and maintaining the intravenous catheter. 
 
The blood pressure, temperature and pulse of the research participants will be measured in the 
pre-hospital clinical evaluation and in the clinical evaluation of hospital discharge. During the 
confinement period, vital signs will be measured at pre-established times according to Table 
6.5.2.1:2. When the time scheduled for the measurement of vital signs coincides with the 
collection time, blood collection should be prioritized, with an interval of ±30 minutes for the 
measurement of vital signs. The measurements that happen to exceed this interval will be 
considered in the clinical report as a protocol deviation. The vital signs measured during the 
confinement period will be described in the clinical study report. Vital signs measured during 
hospitalization that are outside the reference values defined in standard operating procedures 
will be assessed by the physician as to their clinical significance. Only adverse events 
considered clinically significant by the physician will be considered adverse events. 
 
It is important to note that research participants will be released from hospitalization after 12-
hour collection and will return for collections between 24:00, 48:00 and 72:00 hours. For extra 
collections, an interval of ± 1 hour from the actual collection time, as described in the clinical 
protocol, will be accepted. Extra collections performed outside the ± 1 hour interval of the 
actual time will be considered in the clinical report as protocol deviations. For collections made 
during the confinement period, all delays and advances will be considered as a protocol 
deviation. The actual collection times will be described in the clinical report. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 56 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
 
 
Table 6.5.2.1:2. – Activities performed by the research participant during the confinement in periods 1 
and 2. 
 
* If necessary. 
 
 
 
 
 
 
 
Nº of collection 
Time (h) 
Volume collected 
Safety evaluation 
Pre-dose 
C-01 
Before the administration of the 
drug (5 minutes before) 
8 mL 
BP, pulse, temperature 
C-02 
00:15 
8 mL 
 
C-03 
00:30 
8 mL 
 
C-04 
00:45 
8 mL 
 
C-05 
01:00 
8 mL 
BP, pulse, temperature 
C-06 
01:15 
8 mL 
 
C-07 
01:30 
8 mL 
C-08 
01:45 
8 mL 
 
C-09 
02:00 
8 mL 
BP, pulse, temperature 
C-10 
02:20 
8 mL 
 
C-11 
02:40 
8 mL 
 
C-12 
03:00 
8 mL 
BP, pulse, temperature 
C-13 
03:30 
8 mL 
 
C-14 
04:00 
8 mL 
BP, pulse, temperature 
C-15 
04:30 
8 mL 
 
C-16 
05:00 
8 mL 
 
C-17 
05:30 
8 mL 
 
C-18 
06:00 
8 mL 
BP, pulse, temperature 
C-19 
07:00 
8 mL 
 
C-20 
08:00 
8 mL 
 
C-21 
10:00 
8 mL 
 
C-22 
12:00 
8 mL 
BP, pulse, temperature 
C-23 
24:00 
8 mL 
BP, pulse, temperature* 
C-24 
48:00 
8 mL 
BP, pulse, temperature* 
C-25 
72:00 
8 mL 
BP, pulse, temperature* 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 57 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
Procedures for the handling and storage of biological 
samples 
6.5.3.1
Internal transportation of biological samples 
A professional from the samples processing lab will collect the tubes containing the blood 
sample of each one of the research participant, immediately after the collections. These samples 
will be placed in appropriate racks, inside a thermal box, containing solid ice and with 
temperature control (2 - 8°C). 
The internal transportation of biological samples will be performed through ramps, whereas 
the search participant flow, clothes, food, and drugs distribution times must not coincide with 
the internal transportation of the biological samples. 
 
6.5.3.2
Identification of the samples 
All the sample storage tubes must be labeled with the following information: 
• Research participant number (01); 
• Collection number (C-02); 
• Collection time (00:00; 00:15, etc.); 
• Period of treatment (1 or 2); 
• In cases of retain samples: (R); 
• Actives ingredients codes (EMP/MET); 
• Biological matrix (plasma) 
• Number of protocol. 
 
6.5.3.3
Handling, storage and transportation 
The EDTA-anticoagulated blood samples will be centrifuged within 45 minutes after collection 
while stored in an ice water bath. The samples will be centrifuged for approximately 10 min at 
approximately 2000 g to 4000 g and at 4 to 8 °C. Four plasma aliquots will be obtained and 
stored in polypropylene tubes. Each  aliquot should contain at least 0.5 mL of plasma. The 
process from blood collection until transfer of plasma aliquots into the freezer should be 
completed in less than 60 min, with interim storage of blood samples and aliquots in ice water 
or on ice. 
After frozen, the samples will be organized by study period and stored in plastic bags labelled 
with the protocol number, active’s principle code, number of research participants and study 
periods (Period 1 or 2) and in the case of samples retains the description "R".  
The time each aliquot was placed in the freezer will be documented. Until transfer on dry ice 
to the analytical laboratory, the aliquots will be stored upright at approximately -20°C or below 
at the trial site. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 58 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
After the end of the clinical step and freezing, the samples for analysis (first, second and third 
aliquot) must be transferred from 
clinical site to 
 in 
: 
Address: 
 
ZIP CODE: 
 
PHONE/FAX: 
 
E-mail: 
 
 
At the analytical laboratory, the plasma samples will be stored at approximately -20°C or below 
until analysis. 
The amount of dry ice to be used will be enough to keep the samples frozen for at least 72 
hours.  The samples will be shipped to the analytical site, according to the 
 SOP.  The 
packaging of the samples will meet the Biosafety rules and International Air Transport 
Association (IATA) recommendations related to the documentation and package. 
The samples of each subject will be packaged in a heat-sealed plastic bag.  These individual 
sample bags will be grouped at every four and placed in a larger, duly sealed plastic bag.  Then, 
they will be placed into a Styrofoam box, organized as follows: a first layer of dry ice followed 
by the packaged samples, and a second layer of dry ice covering all the samples.  Above this 
second ice layer a layer of newsprint will be placed and the box will be closed.  A cardboard 
box will also be used as outer package.  The shipment will be followed by a letter containing 
the information stated to the Port Health Authorities attached to the outer wall of the cardboard 
package.  This letter will contain a statement signed by the responsible of the clinical phase in 
charge explaining the purpose of the samples shipment, the list of subjects’ initials, as approved 
by the Ethics Committee, and the study drug.  A second copy will be send to the destination 
lab, and another copy will be kept in the 
 Clinical Site. The previous contact will be 
established with the transportation company and the recipient, in order to guarantee that the 
samples are immediately opened and their physical integrity and checked.  The confirmation 
of the shipment will be made by email.  The recipient will be immediately informed of all 
sample delivery data.  The delivery will be made directly to the Analytical Laboratory, and the 
recipient will e-mail a receipt confirmation after confirming its integrity.  A copy of the process 
will be maintained in the 
 for ANVISA consultation. 
The samples will be transported followed by a data logger for temperature control, Delivery 
Check List and Biological Samples Checking listing the box content, the number of samples 
and other information related to the study. 
The person in charge for the analytical step must receive and check the samples immediately 
after receiving them, writing down the temperature at the moment of receipt and signing the 
Delivery Check List and Biological Samples Checking. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 59 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
The Delivery Check List and Biological Samples Checking must be completed at the Analytical 
site.  Any complication, when applicable, must be informed by the Analytical Site technician 
to the 
 clinical site. 
Empagliflozin and Metformin concentrations may be measured either by use of the same or 
different aliquots. 
The retention biological samples (fourth aliquot) will be stored in freezer at approximately -
20°C according to Resolution n° 4418 from May 12, 2011 from Health National Council under 
 responsibility and management of the Principal Researcher and will be discarded after 
Sponsor authorization. 
 
 
 
Analytical determinations 
6.5.4.1
Analytical determination of analyte plasma concentration 
Concentrations of empagliflozin and metformin in plasma will be determined by a validated 
LC-MS/MS (liquid chromatography tandem mass spectrometry) assay at 
, 
. All details of the analytical method will be available prior to the start of sample 
analysis. 
 
During sample analysis, the bioanalyst will be blinded to subject allocation and will have no 
access to the random code.  
6.6 
ASSESSMENT OF BIOMARKER(S)  
Not applicable. 
6.7 
BIOBANKING 
Biological samples will be stored in accordance with Resolution No. 441 of May 12, 2011 of 
the National Health Council, which determines guidelines and conditions to be considered for 
the storage of biological samples, and will be used to verify through a single-dose study, if 
the test treatment (in a combination of 12.5mg of empagliflozin + 850mg of metformin) is 
bioequivalent to Jardiance 10mg references (empagliflozin - Reference 1) and to Glifage 
850mg (metformin - Reference 2) managed together. Any new research to be done with the 
material will be submitted to approval of the CEP/CONEP system (National Research Ethics 
Commission) and the research participant must give their consent to the use of these samples, 
signing a new Informed Consent Form. 
6.8 
OTHER ASSESSMENTS
Not applicable. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 60 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
6.9 
APPROPRIATENESS OF MEASUREMENTS 
All measurements performed during this trial are standard measurements and will be 
performed in order to monitor subjects’ safety and to determine pharmacokinetic parameters 
in an appropriate way. The scheduled measurements will allow monitoring of changes in vital 
signs, standard laboratory values, and ECG parameters that might occur as a result of 
administration of trial medication. The safety assessments are standard, are accepted for 
evaluation of safety and tolerability of an orally administered drug and are widely used in 
clinical trials.  
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 61 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
7. 
INVESTIGATIONAL PLAN 
7.1
VISIT SCHEDULE 
Exact times of measurements will be documented. The acceptable time windows for 
screening and the end of trial examination are provided in the Flow Chart. 
Study measurements and assessments scheduled to occur ‘before’ trial medication 
administration on Day 1 are to be performed and completed within a 2 h-period prior to the 
trial drug administration. 
The acceptable deviation from the scheduled time for vital signs, ECG, and laboratory tests 
will be ± 30 min. 
If scheduled in the Flow Chart at the same time as a meal, vital signs, and 12-lead ECG 
recordings, blood sampling, have to be done first.. 
For planned blood sampling times, refer to the Flow Chart. While these nominal times should 
be adhered to as closely as possible, the actual sampling times will be recorded and used for 
the determination of pharmacokinetic parameters. If a subject misses an appointment, it will 
be rescheduled if possible.  
DETAILS OF TRIAL PROCEDURES AT SELECTED VISITS 
7.2 
 
Screening  
After having been informed about the trial, all subjects will provide written informed consent 
in accordance with GCP and local legislation prior to enrolment in the study. 
For information regarding laboratory tests (including drug and virus screening), ECG, vital 
signs, and physical examination, refer to Sections 5.2.3 to 5.2.5. 
 
Treatment periods 
Each subject is expected to participate in 2 treatment periods (2 Days before treatment -2,-1 
and Days 1, 2, 3, and 4 in each period). At least 7 days will separate drug administrations in 
the first and second treatment periods. 
On Day -1 of each treatment period, study participants will be admitted to the trial site and 
kept under close medical surveillance for at least 12 h following drug administration. The 
subjects will then be allowed to leave the trial site after formal assessment and confirmation 
of their fitness. On all other study days, subjects will be treated in an ambulatory fashion. 
For details on time points and procedures for collection of plasma samples for PK analysis, 
refer to Flow Chart and Section 5.3.2.  
The safety measurements performed during the treatment period are specified in Section 5.3 
of this protocol and in the Flow Chart. For details on times of all other trial procedures, refer 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 62 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
to the Flow Chart. AEs and concomitant therapy will be assessed continuously from 
screening until the end of trial examination. 
 
Follow-up period and trial completion 
For AE assessment, laboratory tests, recording of ECG and vital signs, and physical 
examination during the follow-up period, see Sections 5.2.2 to 5.2.5. 
Subjects who discontinue treatment before the end of the planned treatment period should 
undergo the EoTrial Visit. 
All abnormal values (including laboratory parameters) that are assessed as clinically relevant 
by the investigator will be monitored using the appropriate tests until a return to a medically 
acceptable level is achieved. (S)AEs persisting after a subject’s EoTrial Visit must be 
followed until they have resolved, have been sufficiently characterised, or no further 
information can be obtained.  
 
8. 
STATISTICAL METHODS AND DETERMINATION OF 
SAMPLE SIZE 
8.1
STATISTICAL DESIGN – MODEL 
 
The main objective of this trial is to establish the bioequivalence of 12,5 mg of Empa/ 850 
mg of Met in a FDC tablet (Treatment B) compared with 10 mg of Empa tablet and 850 mg 
tablet of Met (treatment A) following oral administration on the basis of the primary and 
secondary pharmacokinetic endpoints, as listed in Section 2.1.2 and 2.1.3. The trial is 
designed to allow intra-subject comparisons and will be evaluated statistically by use of a 
linear model for logarithmically transformed PK endpoints.  
These pharmacokinetic parameters will be assessed by descriptive statistics.
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 63 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
8.2 
NULL AND ALTERNATIVE HYPOTHESES 
Although there are multiple endpoints, an alpha adjustment is not needed because it is 
required that all primary endpoints and the AUC 0-∞ secondary endpoints meet the 
equivalence criterion as described below simultaneously. Therefore, a one-sided alpha of 5% 
will be used for testing. 
The assessment of bioequivalence will be based upon two-sided 90% confidence intervals 
(CIs) for the ratio of the geometric means (B/A) for the primary and secondary only AUC0-∞ 
endpoint using an acceptance range of 80.00 - to 125.00% for both Empa and Met. This 
method is equivalent to the two-sided t-test procedure, each at the 5% significance level. 
The following hypotheses are tested:  
Null hypothesis H0 (Inequivalence):  
δ
μ
μ
δ
μ
μ
R
T
R
T
≥
−
−
≤
−
or
 
where 
T
µ  and 
R
µ
are the means of the log-transformed endpoint for the test and reference 
treatments, respectively, and δ is the bioequivalence limit that defines the acceptance range 
on the logarithmic scale. Alternative hypothesis Ha (Equivalence): 
δ
μ
μ
δ
R
T
<
−
<
−
 
In this trial, the bioequivalence limit δ is ln(1.25). By back-transforming (exponentiating), 
this translates to an acceptance range of 80.00 to 125.00% for the ratio of the geometric 
means (test/reference) for endpoints on the original scale. 
The rejection of the null hypothesis at the α = 0.05 level is equivalent to the inclusion of the 
90% confidence interval for 
R
T
µ
−
µ
in the acceptance range (-δ, δ). 
8.3 
PLANNED ANALYSES 
Analysis sets 
Statistical analyses will be based on the following analysis sets: 
• Treated Set (TS): The treated set includes all participants in the research that were 
randomized and treated with at least one dose of study medication. The treated set 
will be used for analysis of security. 
• Pharmacokinetic parameter analysis set (PKS): This set includes all subjects who 
provide all PK endpoints for all treatment periods that were defined as primary (Cmax 
and AUC0-tz) and was not excluded due to a protocol violation relevant to the 
evaluation of PK or due to PK non-evaluability (as specified in the following 
subsection ‘Pharmacokinetics’).   Model-based analyses of PK parameters will be 
based on the PKS. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 64 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Adherence to the protocol will be assessed by the trial team. Important protocol deviation 
(iPD) categories will be suggested in the iPD specification file, iPDs will be identified no 
later than in the Report Planning Meeting, and the iPD categories will be updated as needed. 
Pharmacokinetics 
Plasma concentration data and parameters of a subject will be included in the statistical 
pharmacokinetic (PK) analyses if they are not flagged for exclusion due to a protocol 
deviation relevant to the evaluation of PK (to be decided no later than in the Report Planning 
Meeting) or due to PK non-evaluability (as revealed during data analysis, based on the 
criteria specified below). Exclusion of a subject’s data will be documented in the CTR. 
Relevant protocol deviations may be 
• 
Incorrect trial medication taken, i.e. the subject received at least one dose of trial 
medication the subject was not assigned to 
• 
Incorrect dose of trial medication taken 
• 
Use of restricted medications 
Plasma concentrations and/or parameters of a subject will be considered as non-evaluable, if 
for example 
• The subject experienced emesis that occurred at or before two times median tmax of 
the respective analytes (Median tmax is to be determined excluding the subjects 
experiencing emesis). 
• Missing samples/concentration data at important phases of PK disposition curve 
The plasma concentration data and parameters of a flagged research participant for exclusion 
will be reported with their individual values but will not be included in the statistical 
analyses. Descriptive and inferential statistics of PK parameters will be based on the PKS. 
Only concentration values within the validated concentration range will be used for the 
calculation of pharmacokinetic parameters. Concentrations used in the pharmacokinetic 
calculations will be in the same format provided in the bioanalytical report, (that is, to the 
same number of decimal places provided in the bioanalytical report).   
  
 
Primary and key secondary endpoint analyses 
Primary analyses 
The statistical model used for the analysis of the primary endpoints and the key secondary 
endpoint AUC0-inf will be an analysis of variance (ANOVA) model on the logarithmic scale. 
That is, the PK endpoints will be log-transformed (natural logarithm) prior to fitting the 
ANOVA model. This model will include effects accounting for the following sources of 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 65 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
variation: sequence, subjects within sequences, period and treatment. The effect 'subjects 
within sequences' will be considered as random, whereas the other effects will be considered 
as fixed. The model is described by the following equation: 
 
yijkm = µ + ζi + sim + πj + τk + eijkm, where 
 
yijkm = logarithm of response measured on subject m in sequence i receiving treatment   
k in period j, 
 
µ = the overall mean, 
 
ζi = the io sequence effect, i = 1, 2, 
 
sim = the effect associated with the m0 subject in the ia sequence, 
 
m = 1, 2, ..., ni 
 
πj = the j0 period effect, j = 1, 2, 
 
τk = the k0 treatment effect, k = 1, 2, 
 
eijkm = the random error associated with the mth subject in sequence i who received 
 
treatment k in period j. 
where sim ~ N(0, σB
2) i. i. d. , eijkm ~ N(0, σW
2 ) i.i.d. and sim, eijkm are independent random 
variables. 
This analysis will be restricted to subjects that have PK evaluable parameter values for both 
treatment periods. 
Point estimates for the ratios of the geometric means (test/reference) for the primary 
endpoints (see Section 2.1) and their two-sided 90% confidence intervals (CIs) will be 
provided. 
For each endpoint, the difference between the expected means for log(T)-log(R) will be 
estimated by the difference in the corresponding adjusted means (Least Squares Means). 
Additionally, their two-sided 90% confidence intervals will be calculated based on the 
residual error from the ANOVA and quantiles from the t-distribution. These quantities will 
then be back-transformed to the original scale to provide the point estimate and 90% CIs for 
each endpoint. 
Bioequivalence is considered established if the 90% confidence intervals of the geometric 
means for the primary (and secondary AUC0-∞) endpoints are contained in the pre-defined 
acceptance range, see Section 7.2. 
 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 66 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
8.4 
INTERIM ANALYSES 
No interim analysis is planned. 
8.5 
HANDLING OF MISSING DATA 
 
Safety 
It is not planned to impute missing values for safety parameters. 
 
Pharmacokinetics 
PK parameters that cannot be reasonably calculated based on the available drug 
concentration-time data will not be imputed. 
8.6 
RANDOMISATION 
Subjects will be randomised to one of the 2 treatment sequences in a 1:1 ratio. The block size 
will be documented in the CTR. 
The randomization list will be generated using a software developed by 
 
) called vWEB BIO, that will randomize the subjects for each one of the 
sequences automatically, and at the same time, it will stratify the genders (if the study uses two 
genders) of the subjects in a balanced way (treatment A – treatment B [AB] or treatment B – 
treatment A [BA]).  The program developed also estimates (conforming to item 1.k from 
Resolution RE Nº 1170, from April 19th 2006) that the genders (if the study uses two genders) 
are equally distributed/stratified within each sequence in a random way so that stratification 
bias/confounding factors do not compromise the results. 
The randomisation list will contain additional blocks to allow for subject replacement (refer 
to Section 3.3.5). 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 67 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
8.7 
DETERMINATION OF SAMPLE SIZE 
The sample size for this trial was determined using assumptions on the intra-individual 
variability of the primary endpoints based on previous studies -performed at 
For both 
actives, empagliflozin and metformin,Cmax the geometric coefficient of variation (gCV) was 
estimated to be between 9% and 23%, while for AUC the gCV was between 9% and 23%.  
Due to the high correlation between the primary endpoints, only Cmax will be considered for 
power calculations. Using a sample size of 24 subjects (12 per sequence group), the power to 
reject both one-sided null hypotheses for one parameter each at the 5% level of significance 
in favour of bioequivalence is displayed in Table 7.7: 1, under various assumptions for the 
T/R ratio. To account for the uncertainty of the assumed gCV, a range of gCVs around 20% 
is also presented. 
 
Table 7.7: 2 
Power for concluding bioequivalence (acceptance range 80-125%) 
based on a geometric coefficient of variation around 20% and for 
different expected ratios of geometric means (test/reference) in a 2x2 
crossover trial (N=24) 
 
Ratio [%]* 
gCV [%] 
90 
92.5 
95 
97.5 
100 
18 
71.5 
86.1 
94.3 
98.0 
98.9 
20 
63.7 
79.2 
89.6 
95.1 
96.7 
23 
53.8 
68.9 
80.7 
87.8 
90.2 
*Ratio of geometric means (test/reference) for a PK endpoint is defined by exp(µT)/exp(µR). 
 
 
From the above table, a sample size of 24 will yield approximately 90% power to conclude 
bioequivalence for an assumed gCVof 20% if the ratio is not more than 5% different from the 
ratio of 100% which reflects no difference in exposure. In addition, this sample size still 
provides approximately 80% power in case the ratio is not more than 7.5% different from 
100% or the gCV is 23%, and about 70% in case the ratio is 7.5% different from 100% and 
the gCV is 23%. 
Accounting for up to 24 non PK evaluable subjects, a total of N = 24 + 08 subjects subjects 
are planned to be entered into the trial. 
The calculations were performed as described by Diletti et al. [R94-1445] using the function 
power.TOST() and power,TOST() of the R package PowerTOST Version 1.4-7 in R Version 
3.4.2. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 68 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
9. 
INFORMED CONSENT, TRIAL RECORDS, DATA 
PROTECTION, PUBLICATION POLICY, AND 
ADMINISTRATIVE STRUCTURE 
The trial will be carried out in compliance with the protocol, the ethical principles laid down 
in the Declaration of Helsinki, in accordance with the ICH Harmonized Guideline for Good 
Clinical Practice (GCP), relevant BI Standard Operating Procedures (SOPs), the EU 
regulation 536/2014, and other relevant regulations. Investigators and site staff must adhere 
to these principles. 
Standard medical care (prophylactic, diagnostic, and therapeutic procedures) remains the 
responsibility of the subject’s treating physician. 
The investigator will inform the sponsor immediately of any urgent safety measures taken to 
protect the trial subjects against any immediate hazard, as well as of any serious breaches of 
the protocol or of ICH GCP. 
The Boehringer Ingelheim transparency and publication policy can be found on the following 
web page: trials.boehringer-ingelheim.com. The rights of the investigator and of the sponsor 
with regard to publication of the results of this trial are described in the investigator contract. 
As a general rule, no trial results should be published prior to archiving of the CTR. 
The terms and conditions of the insurance coverage are made available to the investigator and 
the subjects and are stored in the ISF. 
 
9.1 
TRIAL APPROVAL, SUBJECT INFORMATION, INFORMED CONSENT 
This trial will be initiated only after all required legal documentation has been reviewed and 
approved by the respective Institutional Review Board (IRB / Independent Ethics Committee 
(IEC and competent authority (CA) according to national and international regulations. The 
same applies for the implementation of changes introduced by amendments. 
 
Prior to a subject’s participation in the trial, written informed consent must be obtained from 
each subject (or the subject’s legally accepted representative) according to ICH-GCP and to 
the regulatory and legal requirements of the participating country. Each signature must be 
personally dated by each signatory and the informed consent and any additional subject-
information form retained by the investigator as part of the trial records. A signed copy of the 
informed consent and any additional subject information must be given to each subject or the 
subject’s legally accepted representative. 
The subject must be given sufficient time to consider participation in the trial. The 
investigator or delegate obtains written consent of the subject’s own free will with the 
informed consent form after confirming that the subject understands the contents. The 
investigator or 
delegate must sign (or place a seal on) and date the informed consent form. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 69 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
If a trial collaborator has given a supplementary explanation, the trial collaborator also signs 
(or places a seal on) and dates the informed consent. 
Re-consenting may become necessary when new relevant information becomes available and 
should be conducted according to the sponsor’s instructions. 
9.2
DATA QUALITY ASSURANCE 
A risk-based approach is used for trial quality management. It is initiated by the assessment 
of critical data and processes for trial subject protection and reliability of the results as well as 
identification and assessment of associated risks. An Integrated Quality and Risk 
Management Plan documents the rationale and strategies for risk management during trial 
conduct including monitoring approaches, vendor management and other processes focusing 
on areas of greatest risk. 
Continuous risk review and assessment may lead to adjustments in trial conduct, trial design 
or monitoring approaches.  
A quality assurance audit/inspection of this trial may be conducted by the sponsor, sponsor’s 
designees, or by IRB / IEC or by regulatory authorities. The quality assurance auditor will 
have access to all medical records, the investigator’s trial-related files and correspondence, 
and the informed consent documentation of this clinical trial. 
9.3 
RECORDS 
CRFs for individual subjects will be provided by the sponsor. See Section 4.1.5 for rules 
about emergency code breaks. For drug accountability, refer to Section 4.1.8. 
 
Source documents 
In accordance with regulatory requirements, the investigator should prepare and maintain 
adequate and accurate source documents and trial records for each trial subject that include 
all observations and other data pertinent to the investigation. Source data as well as reported 
data should follow the ‘ALCOA principles’ and be attributable, legible, contemporaneous, 
original, and accurate. Changes to the data should be traceable (audit trail). 
Data reported on the CRF must be consistent with the source data or the discrepancies must 
be explained. 
Before providing any copy of subjects’ source documents to the sponsor, the investigator 
must ensure that all subject identifiers (e.g., subject’s name, initials, address, phone number, 
and social security number) have properly been removed or redacted to ensure subject 
confidentiality. 
If the subject is not compliant with the protocol, any corrective action (e.g. re-training) must 
be documented in the subject file.
For the CRF, data must be derived from source documents, for example: 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 70 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
• Subject identification: sex, year of birth (in accordance with local laws and 
regulations)
• Subject participation in the trial (substance, trial number, subject number, date subject 
was informed) 
• Dates of subject’s visits, including dispensing of trial medication 
• Medical history (including trial indication and concomitant diseases, if applicable) 
• Medication history 
• AEs and outcome events (onset date [mandatory], and end date [if available]) 
• SAEs (onset date [mandatory], and end date [if available]) 
• Concomitant therapy (start date, changes) 
• Originals or copies of laboratory results and other imaging or testing results, with 
proper documented medical evaluation (in validated electronic format, if available) 
• ECG results (original or copies of printouts) 
• Completion of subject’s participation in the trial (end date; in case of premature 
discontinuation, document the reason for it, if known) 
• Prior to allocation of a subject to a treatment into a clinical trial, there must be 
documented evidence in the source data (e.g. medical records) that the trial participant 
meets all inclusion criteria and does not meet any exclusion criteria. The absence of 
records (either medical records, verbal documented feedback of the subject or testing 
conducted specific for a protocol) to support inclusion/exclusion criteria does not 
make the subject eligible for the clinical trial. 
 
 
Direct access to source data and documents 
The investigator /institution will allow site trial-related monitoring, audits, IRB / IEC review 
and regulatory inspections. Direct access must be provided to the CRF and all source 
documents/data, including progress notes, copies of laboratory and medical test results, which 
must be available at all times for review by the Clinical Research Associate, auditor and 
regulatory inspector (e.g. FDA). They may review all CRFs and informed consents. The 
accuracy of the data will be verified by direct comparison with the source documents 
described in section 8.3.1. The sponsor will also monitor compliance with the protocol and 
GCP. 
 
Storage period of records 
Trial site: 
The trial site(s) must retain the source and essential documents (including ISF) according to 
contract and the local requirements valid at the time of the end of the trial. 
Sponsor: 
The sponsor must retain the essential documents according to the sponsor’s SOPs. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 71 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
9.4
EXPEDITED REPORTING OF ADVERSE EVENTS 
BI is responsible to fulfil their legal and regulatory reporting obligation in accordance with 
regulatory requirements. 
9.5 
STATEMENT OF CONFIDENTIALITY AND SUBJECT PRIVACY 
Individual subject data obtained as a result of this trial is considered confidential and 
disclosure to third parties is prohibited with the exceptions noted in section 8.7.  
Data protection and data security measures are implemented for the collection, storage and 
processing of patient data in accordance with the principles 6 and 12 of the WHO GCP 
handbook. 
Personalised treatment data may be given to the subject’s personal physician or to other 
appropriate medical personnel responsible for the subject’s welfare. Data generated at the site 
as a result of the trial need to be available for inspection on request by the participating 
physicians, the sponsor’s representatives, by the IRB / IEC and the regulatory authorities.  
 
Collection, storage and future use of biological samples 
and corresponding data 
The biological samples will be stored for non-commercial use in accordance with Resolution 
No. 441 of May 12, 2011 of the National Health Council, which provides guidelines and 
conditions to be considered for storing  biological samples, and will be used to To establish 
whether a fixed-dose tablet of 12.5 mg empagliflozin+850 mg metformin (T1) is bioequivalent 
to the free dose combination of 10 mg Jardiance (empagliflozin – Reference 1) and Glifage 
850 mg (metformin – Reference 2) (R). 
 Every new research will be submitted for approval of the CEP / CONEP system (National 
Committee for Research Ethics) and you must consent the use of these samples, by signing a 
new free and informed consent form. 
Biological samples are stored in storage tubes identified by its research participant number with 
the aim of maintaining confidentiality and secrecy. 
 
9.6 
TRIAL MILESTONES 
The start of the trial is defined as the date of the enrolment of the first subject in the trial. 
The end of the trial is defined as the ‘date of the last visit of the last subject in whole trial’ 
(‘Last Subject Completed’) or ‘end date of the last open AE’ or ‘date of the last follow-up 
test’ or ‘date of an AE has been decided as sufficiently followed-up’, whichever is latest. 
Early termination of the trial is defined as the premature termination of the trial for any 
reason before the end of the trial as specified in this protocol. 
Temporary halt of the trial is defined as any unplanned interruption of the trial by the 
sponsor with the intention to resume it. 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 72 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
Suspension of the trial is defined as an interruption of the trial based on a Health Authority 
request. 
9.7 
ADMINISTRATIVE STRUCTURE OF THE TRIAL 
The trial is sponsored by Boehringer Ingelheim (BI). 
The trial will be conducted at 
, under the supervision of the Principal 
Investigator. Relevant documentation on the participating (Principal) Investigators (e.g. their 
curricula vitae) will be filed in the ISF. 
BI has appointed a Trial Clinical Monitor, responsible for coordinating all required trial 
activities, in order to  
• Manage the trial in accordance with applicable regulations and internal SOPs 
• Direct the clinical trial team in the preparation, conduct, and reporting of the trial 
• ensure appropriate training and information of local clinical monitors (CML), Clinical 
Research Associates, and investigators of participating trial sites 
The trial will be conducted at the 
, under the supervision of the principal 
investigator.  
The trial medication will be provided by 
 
  
Safety laboratory tests will be performed by the local laboratory of the trial site (
 to 
inform)  
The analyses of empagliflozin and metformin concentrations in plasma will be performed at 
. 
The trial is sponsored by 
. 
On-site monitoring will be performed by BI or a contract research organisation appointed by 
BI. 
Data management and statistical evaluation will be done by 
 and BI according to BI 
SOPs.  
Tasks and functions assigned in order to organise, manage, and evaluate the trial are defined 
according to BI SOPs. A list of responsible persons and relevant local information can be 
found in the ISF. 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 73 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
10. 
REFERENCES  
10.1 
PUBLISHED REFERENCES 
R03-2269 
Guidance for industry: food-effect bioavailability and fed bioequivalence 
studies. In: U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research (CDER) 2002:1-
9. 
R11-5230 
Julious SA. Sample sizes for clinical trials. Boca Raton: Taylor & Francis 
Group; 2010. 
R15-1331 
Elashoff JD. nQuery Advisor version 7.0 user's guide. 
http://www.statsols.com/wp-
content/uploads/2013/10/nQ70_version2_manual.pdf  
(access date: 20 March 2015) ; Los Angeles: Statistical Solutions; 2007.  
R94-1445 
Diletti E, Hauschke D, Steinijans VW. Sample size determination for 
bioequivalence assessment by means of confidence intervals. Int J Clin 
Pharmacol Ther Toxicol 1992; 30 (suppl 1): S51-S58. 
R94-1529  
Chow SC, Liu JP, editors. Design and analysis of bioavailability and 
bioequivalence studies. New York: Marcel Dekker Inc., 1992. 
10.2 
UNPUBLISHED REFERENCES 
001-MCS-36-472 Standards and processes for analyses performed within Clinical 
Pharmacokinetics/Pharmacodynamics. Current version 
c01678844-16     Empagliflozin Investigator’s Brochure 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol
Page 74 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
BI-KMED-PV-CLT-0015    POTENTIAL DRUG-INDUCED LIVER INJURY (DILI) 
CHECKLIST APPENDICES 
Randomization list (in Portuguese) 
Anexo1_Randomiza
cao.pdf
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 75 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
11. 
DESCRIPTION OF GLOBAL AMENDMENT(S) 
This is the original protocol.  
11.1 
GLOBAL AMENDMENT 1 
Date of amendment 
  
<Give the date of the final revised CTP, i.e. the 
date of the global amendment, in the format 
dd Mmm yyyy> 
EudraCT number 
EU number 
 
 
BI Trial number 
 
 
BI Investigational Medicinal 
Product(s) 
 
 
Title of protocol 
 
 
 
 
  
To be implemented only after approval of the IRB / IEC / Competent 
Authorities 
 
To be implemented immediately in order to eliminate hazard – IRB / IEC / 
Competent Authority to be notified of change with request for approval 
 
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only 
 
 
Section to be changed 
 
 
 
Description of change 
 
 
 
Rationale for change 
 
 
 
 
11.2 
GLOBAL AMENDMENT 2 
Date of amendment 
  
<Give the date of the final revised CTP, i.e. the 
date of the global amendment, in the format 
dd Mmm yyyy> 
EudraCT number 
EU number 
 
 
BI Trial number 
 
 
BI Investigational Medicinal 
Product(s) 
 
 
Title of protocol 
 
 


Boehringer Ingelheim 
08 Jun 2021 
BI Trial No.: 1276-0041 
  
 number: PBDS004/21 
<c12345678-01> 
 
 
Trial Protocol 
Page 76 of 76 
Proprietary confidential information © 2021 Boehringer Ingelheim International GmbH or one or more of its affiliated companies 
 
001-MCS-40-106-RD-13 (6.0) / Saved on: 13 Jun 2018 
 
 
  
To be implemented only after approval of the IRB / IEC / Competent 
Authorities 
 
To be implemented immediately in order to eliminate hazard – IRB / IEC / 
Competent Authority to be notified of change with request for approval 
 
Can be implemented without IRB / IEC / Competent Authority approval as 
changes involve logistical or administrative aspects only 
 
 
Section to be changed 
 
 
 
Description of change 
 
 
 
Rationale for change